




10/006,611

Attachment #10



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 1 036 844 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

20.09.2000 Bulletin 2000/38

(51) Int. Cl.⁷: C12N 15/12, C12N 15/54,
C12N 15/63, C12Q 1/68,
C07K 16/40, A61K 48/00,
A61K 38/43, A61K 33/32

(21) Application number: 98955971.1

(22) Date of filing: 27.11.1998

(86) International application number:
PCT/JP98/05357(87) International publication number:
WO 99/28459 (10.06.1999 Gazette 1999/23)(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE(72) Inventors:
• JENNE, Dieter, E.
D-82061 Neuried (DE)
• NEZU, Jun-Ichi,
Chugai Res.Inst Molec. Medic.Inc.
Ibaraki 300-4101 (JP)(30) Priority: 27.11.1997 JP 34425697
01.10.1998 JP 28035798(74) Representative:
Jaenichen, Hans-Rainer, Dr.
Vossius & Partner,
Postfach 86 07 67
81634 München (DE)(71) Applicant:
Chugai Research Institute for Molecular
Medicine Inc.
Niihari-gun, Ibaraki 300-4101 (JP)(54) **EXAMINATION METHOD, EXAMINATION REAGENT AND REMEDY FOR DISEASES CAUSED BY VARIATION IN LKB1 GENE**

(57) With respect to a range of 1.5 Mbp and more in the chromosome 19p13.3 region containing Peutz-Jeghers gene, a continuous cosmid contig is constructed and a restriction map is prepared. Next, genes mapped with this region are searched by using EST database and the locations of these genes are accurately determined. Based on the evaluation of biological data, etc., several highly likely candidates for Peutz-Jeghers genes are specified from the genes thus found. After successively analyzing variations in these genes in DNAs of patients with Peutz-Jeghers syndrome, it is found that one of these genes, i.e., "LKB1" has been specifically varied in these patients. Thus, the diseases caused by the variation in the LKB1 gene can be diagnosed and treated by using the LKB1 gene, primers and probes based on its base sequence, LKB1 protein, an antibody binding to this protein, etc.

Description**Technical Field**

5 [0001] The present invention relates to a method of diagnostic of the diseases caused by mutations in the LKB1 gene and to an diagnostic reagent and a therapeutic preparation for said diseases.

Background Art

10 [0002] Peutz-Jeghers (PJ) syndrome [MIM 175200] is an autosomal dominantly inherited disorder characterized by melanotic pigmentation of lips, perioral and buccal regions and by benign, hamartomatous and adenomatous types of multiple gastrointestinal polyps. Patients with this syndrome are known to frequently develop benign or malignant neoplasms in the gastrointestinal tract, pancreas, ovaries, testis, breast and uterus. In particular, small benign tumors frequently occur in the ovary and are developed as multifocal, symmetrical germinal-cord structures with annular tubules.
 15 Then, they progress into granulosa cancer and result in ambisexual precocity in girls. It was found that multifocal germinal cord cancer in boys, though with low frequency, results in gynecomastia and feminization due to over-production of estrogen. Defects in the gene responsible for Peutz-Jeghers syndrome (PJ gene) appear to predispose to a wide spectrum of neoplastic diseases. In fact, 50% of the carriers with a defect in one of PJ allele are known to develop cancer by the age of 60 (Giardello, F.M. et al. Increased risk of cancer in Peutz-Jeghers syndrome. N. Engl. J. Med. 316, 1511-1514 (1987); Spigelman, A.D., Murday, V. & Phillips, R.K. Cancer and Peutz-Jeghers syndrome. Gut 30, 1588-1590 (1989). [MIM 175200]). It is believed that loss or inactivation of the PJ gene product results in disruption of the fundamental growth control mechanism within somatic cells that have potential high proliferative capacity, which triggers the growth of benign hamartomatous polyps some of which turn into malignant tumor cells after further genetic alteration.
 20 [0003] Recently, it was reported that PJ gene was mapped to chromosome 19p13.3 by linkage analysis in 12 families of PJ syndrome with a multipoint lod score of 7.00 at the microsatellite genetic marker D19S886 (Hemminki, A. et al. Localization of a susceptibility locus for PJ syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat. Genet. 15 (1), 87-90 (1997)). A similar linkage between PJ gene and the genetic marker D19S886 was reported in a second study investigating five other families as well (with a multipoint lod score of 7.52)
 25 (Amos, C.I. et al. Fine mapping of a genetic locus for PJ syndrome on chromosome 19p. Cancer Res. 57, 3653-3656 (1997)). D19S565 was first known as a genetic marker proximal to the PJ gene, which causes recombination with the gene. Thereafter, the genetic marker D19S878 was found to be located more proximal to the gene. These two makers, therefore, were thought to define the proximal border of the PJ candidate region. In both linkage studies, no recombination was observed between the marker D19S886 and PJ gene, indicating that they are located in a narrow interval.
 30

Disclosure of the Invention

[0004] An objective of the present invention is to identify the gene responsible for Peutz-Jeghers syndrome and to provide a method for diagnosing diseases resulting from a mutation in this gene, a diagnostic reagent and a therapeutic preparation for the diseases.
 40

[0005] To identify the gene for PJ syndrome, the present inventors made a continuous cosmid contig and a restriction map for the region extending from 1.5 Mb within chromosome 19p13.3 which includes the PJ gene. EST database search for the genes mapped in this region was then performed, and the precise locations of these genes were determined. The inventors evaluated biological information of a number of genes thus found and selected several potent candidates of the PJ gene. Mutation analysis of these candidate genes in DNAs from patients with PJ syndrome revealed that one of the candidate genes, "LKB1," was specifically mutated in the patients with PJ syndrome. Thus, the inventors' intense investigations successfully identified the gene responsible for PJ syndrome for the first time. Based on this finding, the inventors found that diseases caused by mutations in the LKB1 gene can be diagnosed and treated by utilizing the LKB1 gene, primers and probes based on the sequence thereof, LKB1 protein and antibodies that bind to LKB1 protein.
 50

[0006] As described above, the present invention relates to a method of diagnosing diseases caused by mutation in the LKB1 gene, the gene responsible for PJ syndrome, and to a diagnostic reagent and a therapeutic preparation for the diseases. More specifically, the present invention relates to:

- 55 (1) a primer DNA used for diagnosing a disease caused by mutation in the LKB1 gene, the primer DNA comprising a nucleotide sequence containing at least a portion of any one of the nucleotide sequences shown in SEQ ID NOs: 1 to 4;
 (2) the primer DNA according to (1), wherein the primer DNA has a nucleotide sequence corresponding to any one

EP 1 036 844 A1

of the nucleotide sequences shown in SEQ ID NOs: 7 to 30;

(3) the primer DNA according to (1) or (2), wherein the disease caused by mutation in the LKB1 gene is Peutz-Jeghers syndrome;

5 (4) a probe DNA used for diagnosing a disease caused by mutation in the LKB1 gene, the probe DNA comprising a nucleotide sequence containing at least a portion of any one of the nucleotide sequences shown in SEQ ID NOs: 1 to 4;

(5) the probe DNA according to (4), wherein the disease caused by mutation in the LKB1 gene is Peutz-Jeghers syndrome;

10 (6) a therapeutic preparation for a disease caused by mutation in the LKB1 gene, the preparation comprising the LKB1 gene as an active ingredient;

(7) a therapeutic preparation for a disease caused by mutation in the LKB1 gene, the preparation comprising the LKB1 protein an active ingredient;

15 (8) a therapeutic preparation for a disease caused by mutation in the LKB1 gene, the preparation comprising a compound that enhances the activity of LKB1 protein as an active ingredient;

(9) the therapeutic preparation according to (6) to (8), wherein the disease caused by mutation in the LKB1 gene is Peutz-Jeghers syndrome;

20 (10) a reagent for diagnostic of a disease caused by mutation in the LKB1 gene, the reagent comprising an antibody that binds to the LKB1 protein as an active ingredient;

(11) the reagent according to (10), wherein the disease caused by mutation in the LKB1 gene is Peutz-Jeghers syndrome;

25 (12) a method of diagnosing a disease caused by mutation in the LKB1 gene, the method comprising detecting mutation in the LKB1 gene;

(13) a method of diagnosing a disease caused by mutation in the LKB1 gene, the method comprising the steps of:

25 (a) preparing a DNA sample from a patient;

(b) amplifying the DNA using the primer DNA according to (1) ;

(c) cleaving the amplified DNA;

(d) fractionating the DNA fragments according to their size;

(e) hybridizing the probe DNA according to (4) with the fractionated DNA fragments; and

30 (f) comparing the size of the DNA fragment thus detected to that from a control of a healthy subject;

(14) a method of diagnosing a disease caused by mutation in the LKB1 gene, the method comprising the steps of:

35 (a) preparing a RNA sample from a patient;

(b) fractionating the RNA sample depending on its size;

(c) hybridizing the probe DNA according to (4) with the RNA thus fractionated;

(d) comparing the size of the RNA thus detected to that from a control of a healthy subject;

40 (15) a method of diagnosing a disease caused by mutation in the LKB1 gene, the method comprising the steps of:

(a) preparing a DNA sample from a patient;

(b) amplifying the DNA using the primer DNA according to (1) ;

(C) separating the amplified DNA into single stranded DNA;

(d) fractionating the separated single stranded DNA on a non-denatured gel;

45 (e) comparing the mobility of the single stranded DNA separated on the non-denatured gel to that of a control of a healthy subject;

(16) a method of diagnosing a disease caused by mutation in the LKB1 gene, the method comprising the steps of:

50 (a) preparing a DNA sample from a patient;

(b) amplifying the DNA using the primer DNA according to (1);

(c) fractionating the amplified DNA on the DNA denatured gradient gel;

(d) comparing the mobility of the fractionated DNA on the gel to that of a control of a healthy subject;

55 (17) the method according to any one of (12) to (16), wherein the disease caused by mutation in the LKB1 gene is Peutz-Jeghers syndrome.

[0007] The present invention was made based on the inventors' findings that Peutz-Jeghers syndrome is caused

by a mutation in the gene called "LKB1". The present invention primarily relates to the use of polynucleotides containing at least a portion of the nucleotide sequence corresponding to the genomic DNA coding LKB1 (including intron, promoter, and enhancer regions as well as exon regions), and said polynucleotides for diagnosing diseases resulting from mutations in the LKB1 gene. The genomic DNA regions of LKB1 are shown in the SEQ ID: 1 to 4. The sequences shown in SEQ ID: 1 to 4 correspond to 5' upstream region, exon 1 and intron 1 (a part) region, exons 2 to 8 and introns 1 (a part) to 8 (a part) region, and intron 8 (a part) and exon 9 region of the LKB1 gene, respectively.

[0008] Nucleotide sequences containing a portion of these regions can be used as primers or probes to diagnose the diseases resulting from mutations in the LKB1 gene. A nucleotide used as a primer is typically 15 to 100 bp, preferably 17 to 30 bp. Any primer can be used as long as it amplifies at least a portion of the LKB1 gene or regions regulating the gene expression. Such regions include, for example, exon, intron, promoter, and enhancer regions of the LKB1 gene. On the other hand, nucleotides used as a probe typically have a sequence of at least 15 bp or more when the nucleotides are synthetic oligonucleotides. Double stranded DNA obtained from a clone into which a vector such as plasmid DNA is incorporated can be used as a probe. For a region utilized as a probe, any part of the LKB1 gene or region regulating the expression thereof can be used. Such regions include, for example, exon, intron, promoter and enhancer regions of the LKB1 gene. When used as a probe, oligonucleotide or double stranded DNA is used after adequately labeling. Labeling methods, for example, include labeling of the 5'-terminus by phosphorylating with ^{32}P using T4 polynucleotide kinase, and labeling by incorporation of substrate bases labeled with isotopes such as ^{32}P , fluorochrome or biotin using DNA polymerases such as Klenow enzyme and primers such as random hexamer oligonucleotides (random-primer method).

[0009] The diseases detectable using these nucleotides, which are caused by mutations in the LKB1 gene are not limited to Peutz-Jeghers syndrome. Any disease caused by mutations in the LKB1 gene is included. PTEN and APC genes were discovered as causative genes for Cowden's disease, which is one of hereditary cancers, and Familial Adenomatous polyposis (FAP), respectively. Both genes proved to be mutated with high frequency in the non-hereditary common cancers. PTEN and APC genes function to control cell proliferation in the normal tissues, and it is believed that a critical step in tumorigenesis occurs when these genes mutate and lose their functions resulting in cells escaping from the regulation of these genes. Similar to PTEN and APC genes, a mutation in the LKB1 gene possibly plays a part in common tumorigenesis.

[0010] The diagnostic method of the diseases caused by mutations in the LKB1 gene in the present invention features detection of mutations in the LKB1 gene. In the present invention, by the term "the diagnosis of the diseases caused by mutations in the LKB1 gene" is meant not only the testing of patients who have developed the particular symptoms resulting from a mutation in the LKB1 gene, but also testing a mutation in the LKB1 gene for determining whether the subject has a predisposition to the particular disease resulting from a mutation in the LKB1 gene. A mutation in one of allele of the LKB1 gene is thought to largely increase the risk for a particular disease caused by mutations in the LKB1 gene even if the symptom has not apparently been developed. The present invention also includes a diagnostic method for identifying patients who have a mutation in one of allele of the LKB1 gene (carriers). "Detection of a mutation in the LKB1 gene" in the present invention includes detection in DNA, RNA and protein.

[0011] One embodiment of the diagnostic method of the present invention is a method of directly determining the nucleotide sequence of the LKB1 gene of a patient. For example, sequencing is performed after amplifying the whole or a partial sequence of the LKB1 gene of a patient using a technique such as PCR (Polymerase Chain Reaction), using the nucleotides described above as primers, and the DNA isolated from a patient who is suspected of being afflicted with a disease caused by a mutation in the LKB1 gene, as template. The sequence thus determined can be used to diagnose the diseases caused by mutations in the LKB1 gene by comparing it to the sequence of the LKB1 gene from healthy subjects.

[0012] In addition to the methods as described above in which DNA from a patient is directly sequenced, different methods can be used as diagnostic methods of the present invention. One of such embodiments comprises the steps of (a) preparing DNA samples from patients, (b) amplifying the DNA from the patients using the primer DNA of the present invention, (c) separating the amplified DNA into the single stranded DNA, (d) fractionating the single stranded DNA separated on non-denaturing gel, and (e) comparing the mobility of the single stranded DNA separated on the gel to that of a control of ordinary person.

[0013] Such methods include PCR-SSCP (single-strand conformation polymorphism; polymorphism of single-stranded DNA in higher-order structure) method (Cloning and polymerase chain reaction-single-strand conformation polymorphism analysis of anonymous Alu repeats on chromosome 11. Genomics. 1992 Jan 1; 12(1): 139-146., Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene. 1991 Aug 1; 6(8): 1313-1318., Multiple fluorescence-based PCR-SSCP analysis with postlabeling., PCR Methods Appl. 1995 Apr 1;4(5):275-282.). Having the advantage of relatively simple manipulation and smaller sample volume requirement, this method is particularly suitable for screening a large number of DNA samples. The principles of the method are as follows: when double stranded DNA fragments are denatured into single stranded DNA, each single stranded DNA forms an original higher-order structure peculiar to its nucleotide sequence;

these denatured DNA, even if they are complementary to each other and have the same chain-length, migrate to distinct positions according to their conformation when electrophoresed on a non-denaturing polyacrylamide gel; the conformations of these single stranded DNA are altered by substitution of a single nucleotide and the substituted DNA migrate with different mobility by electrophoresis on polyacrylamide gel; and thus, detection of the alteration in the 5 mobility enables the detection of mutations such as point mutation, deletion or insertion in the DNA fragment of the interest.

[0014] In the PCR-SSCP method, the whole or a portion of the LKB1 gene is initially amplified using a technique such as PCR. A nucleotide sequence ranging in length from about 200 to 400 bp is typically preferred as a fragment to be amplified. Portions to be amplified include an exon, intron, promoter and enhancer of the LKB1 gene. PCR can be 10 performed under the conventional conditions (for example, the conditions used for amplification of each exons using the primers shown in example 5). On amplifying the gene fragment by PCR, DNA fragments to be synthesized in the PCR reaction may be labeled with primers labeled with an isotope such as ^{32}P , fluorochrome or biotin, or by adding substrate nucleotides labeled with an isotope such as ^{32}P , fluorochrome or biotin in the PCR reaction solution. The said DNA fragments may also be labeled by adding substrate nucleotides labeled with an isotope such as ^{32}P , fluorochrome or biotin 15 to the synthesized DNA fragments by using Klenow enzyme after the PCR reaction. The labeled DNA fragments thus obtained are denatured by heat, for example, and electrophoresed on a polyacrylamide gel without any denaturing agent, such as urea. As to the electrophoresis, conditions for fractionating DNA fragments can be improved by adding an appropriate amount of glycerol (5 to 10%) to polyacrylamide. Conditions for electrophoresis vary depending on the 20 nature of each DNA fragment. Electrophoresis is typically performed at room temperature (20 to 25°C), but when preferable fractionation is not obtained, in the temperature ranging from 4 to 30°C, it is better to test the optimal mobility to determine the temperature which gives the most desirable mobility. After the electrophoresis, mobility of the DNA fragment is detected and analyzed by autoradiography using X-ray films and by scanner for detection of fluorescence. When the bands with different mobility are detected, those bands are directly dissected from the gel, re-amplified by 25 PCR, and subjected to direct sequencing to confirm the mutation. In case where DNA fragments synthesized by PCR are not labeled, the bands of said DNA fragments may be detected using staining techniques such as ethidium bromide or silver staining.

[0015] Another embodiment of the diagnostic methods of the present invention comprises the steps of (a) preparing a DNA sample from a patient, (b) amplifying the DNA derived from the patient using the DNA primers of the present invention, (c) cleaving the DNA thus amplified, (d) fractionating the DNA fragments depending on their size, (e) hybridizing the DNA fragments thus fractionated with the probe DNA of the present invention, and (f) comparing the length of the 30 DNA fragment thus detected to that from healthy subjects.

[0016] These methods include the methods utilizing restriction fragment length polymorphism (RFLP) and PCR-RFLP method. These methods are based on the principle that when a mutation has occurred in the recognition site for a restriction enzyme or when insertion or deletion of bases has occurred in the DNA fragments generated by treatment 35 with a restriction enzyme, the length of those fragments treated with the restriction enzyme generally deviates from that of normal subjects. In fact, for Peutz-Jeghers syndrome, in the LKB1 gene of the four patients shown as samples, D, B, MA and FA, with Peutz-Jeghers syndrome, acquisition of Scal site, elimination of Ahdl, RsaI, and BsrBI site had occurred, respectively (Table 3). Therefore, these mutations can be detected as the differences of bands' mobility after electrophoresis, which was performed after the portions containing these mutations are amplified by PCR and then 40 treated with the restriction enzymes mentioned above. Alternatively, the mutations can be detected by subjecting DNA from patients to southern blotting using the probe DNA of the present invention, after the DNA is treated with these restriction enzymes and electrophoresed. Restriction enzymes used other than those mentioned above are properly selected depending on each mutation. In this method, besides detecting the mutations via restriction enzyme treatment of genomic DNA prepared from patients, cDNA prepared by the treatment of RNA prepared from patients with reverse 45 transcriptase is directly treated with the restriction enzyme and then can be used for southern blotting to detect mutations. This cDNA can also be used as a template for PCR, and the amplified product thereof (the whole or a portion of the LKB1 gene) can be digested with a restriction enzyme and then electrophoresed to detect mutations shown as difference of mobility of the DNA fragments.

[0017] RNA prepared from patients may be used for the detection instead of DNA. Such a method comprises the 50 steps of (a) preparing an RNA sample from a patient, (b) fractionating the prepared RNA depending on the size, (c) hybridizing the RNA thus fractionated to the DNA probe of the present invention, and (d) comparing the size of the RNA fragment thus detected to that from normal subjects. Specifically, RNA prepared from a patient is electrophoresed and subjected to northern blotting to detect the difference of mobility.

[0018] Other embodiments of the diagnostic methods of the present invention comprise the steps of (a) preparing 55 a DNA sample from a patient, (b) amplifying the DNA derived from the patient using the primers of the present invention, (c) fractionating the amplified DNA by electrophoresis on the denaturing gradient gel, (d) comparing the mobility of the DNA on the gel fractionated to that from normal subjects.

[0019] A similar method includes denaturant gradient gel electrophoresis (DGGE) method. In this method, the

whole or a portion of the LKB1 gene is amplified by PCR using primers of the present invention, for example, and electrophoresed on the polyacrylamide gel in which the concentration of a denaturant such as urea gradually increases as the DNA migrate through the gel. The mobility of the DNA is compared to that of normal subjects. If a DNA fragment contains a mutation, it comes to be melted into single stranded DNA in the point of lower denaturant concentration and is remarkably retarded in mobility, and detection of such difference of mobility allows detection of a mutation.

[0020] Besides these methods, allele specific oligonucleotide (ASO) hybridization method can be used for the purpose of only detecting only a mutation in a specific position. In this method, an oligonucleotide containing sequence supposed to have a mutation is synthesized and hybridized with a DNA sample. If the DNA sample has a mutation, the efficiency of hybridization decreases, and this decrease is detected using techniques such as southern blotting and the method of utilizing the fluorescence quenching property of specific fluorescent reagents, which are quenched when intercalated into the gap between the hybrids.

[0021] Ribonuclease A mismatch cleavage may also be used for the detection. In this method, the whole or a portion of the LKB1 gene is amplified by PCR, for example, and the amplified DNA is subjected to hybridization with labeled RNA prepared from LKB1 cDNA or and such, which is inserted into a plasmid vector and such. This hybrid forms single stranded structures at the sites of mutation, and said sites may be cleaved by ribonuclease A and then detected using some method such as autoradiography. Presence of mutations, can be thus detected.

[0022] The present invention relates to a diagnostic reagent for diseases caused by mutations in the LKB1 gene, wherein the reagent comprises, as an active ingredient, an antibody, which binds to the LKB1 protein. Antibodies, which bind to LKB1 protein, can be prepared according to methods well known in the art. As for polyclonal antibodies, for example, a small animal such as a rabbit is immunized with the LKB1 protein (a natural protein as well as a recombinant LKB1 protein expressed in suitable host cells (*E.coli*, yeast or mammalian cells), such as LKB1 protein expressed as a fusion protein with GST in *E.coli*) or its partial peptide(for example, peptide composed of amino acid sequence shown in the SEQ ID: 31 or 34) to obtain antiserum, which then can be purified and prepared using a method such as ammonium sulfate precipitation, protein A, protein G column, DEAE ion exchange chromatography, affinity columns coupled with LKB1 protein or synthetic peptide. For monoclonal antibodies, for example, a small animal such as a mouse is immunized with LKB1 protein or a part of the peptide, and then dissected to remove the spleen. The spleen is homogenized to isolate the cell fraction. These cells are fused with mouse myeloma cells and a reagent such as polyethylene glycol to create fusion cells (hybridomas). From the hybridoma cells thus generated, an appropriate clone which produces an antibody which binds to LKB1 protein is selected. Subsequently, the hybridoma cells thus obtained are intraperitoneally transferred into a mouse, ascites is harvested from the same mouse, and the monoclonal antibody thus obtained can be prepared by purifying by means of, for example, ammonium sulfate precipitation, protein A, protein G column, DEAE ion exchange chromatography, affinity columns coupled with LKB1 protein or synthetic peptide.

[0023] When used as a reagent, the antibody is, if necessary, mixed with sterile water, physiological saline, vegetable oils, surface active agent, lipids, solubility increasing agent, stabilizers (e.g. BSA and gelatin), and preservatives and such. In a test using said antibody, a tissue or cells from a patient are stained using a method such as enzyme-labeled or fluorescence-labeled antibody technique to detect deficiency, aberrant accumulation, or unusual intracellular distribution of LKB1 protein. Alternatively, the protein, which is fractionated from cell extracts prepared from a tissue or cells from patients with Peutz-Jeghers syndrome using a method such as SDS-PAGE, is transferred onto a membrane such as nitrocellulose or PVDF, and detected using a staining method such as enzyme-labeled technique above (western blotting, immunoblotting).

[0024] By constructing a detailed physical map of 19p13.3 region, the inventors revealed that the disease-related gene LKB1 for Peutz-Jeghers syndrome is located in the close proximity of a microsatellite marker D19S886, i.e. their distance on chromosome is about 190 kb. Therefore, the loss of heterozygosity (LOH) test utilizing D19S886 marker may effectively serve as a test for diagnosing various diseases based on mutations in the LKB1 gene.

[0025] The present invention also relates to a therapeutic preparation for diseases caused by mutations in the LKB1 gene. In one embodiment, it comprises the LKB1 gene as an active ingredient. When the LKB1 gene is used as a therapeutic preparation, the whole or a portion of the genomic LKB1 DNA, or the LKB1 cDNA (SEQ ID: 5) is incorporated into an appropriate vector, such as adenovirus vector, adenoassociated virus vector, retrovirus vector, and plasmid DNA, and administered orally, intravenously, or topically to the patient. As a method of administration, *ex vivo* administration can be used as well as *in vivo* administration. In administration of a drug, enclosing the gene into a liposome generated by micellization of phospholipids can enhance the mobility and intake of the gene into the tissue. Alternatively, cationic lipids may be added to form a complex with DNA, which can enhance the mobility and intake of the gene into the tissue. Using these methods, the LKB1 gene mutated in the patient can be substituted by a normal gene, or the normal gene can be additionally administered to the patient, resulting in the possible treatment of a disease caused by a mutation in LKB1 gene.

[0026] Another embodiment of a therapeutic preparation for the diseases caused by mutations in the LKB1 gene, comprises the LKB1 protein as an active ingredient. The LKB1 protein may be prepared as a natural protein or a recombinant protein by utilizing a recombinant DNA technology. The amino acid sequence of the LKB1 protein is shown in

SEQ ID: 6. A natural protein may be isolated using well-known methods. For example, it can be isolated from the cultured cells of the testis, fetal liver or K562 cell, in which the LKB1 protein is expressed at a high level, and by affinity column chromatography using an antibody against a partial peptide of the LKB1 protein described in Example 7. On the other hand, a recombinant protein can be prepared by culturing cells transformed by DNA (SEQ ID: 5) encoding

5 LKB1 protein. Cells that can be used to produce a recombinant protein include mammalian cells, such as COS, CHO, and NIH3T3 cells; insect cells, such as Sf9 cells; yeast ; and *E. coli*. The vectors suitable for expressing a recombinant protein intracellularly depend on the host cells, for example, pcDNA3 (Invitrogen) or pEF-BOS (Nucleic Acids. Res. 1990, 18(17), p.5322) vector is used for mammalian cells; "BAC-to-BAC baculovirus expression system" (GIBCO BRL) for insect cells; "Pichia Expression Kit" (Invitrogen) for yeast; and pGEX-5X-1 (Pharmacia) and "QIAexpress system" 10 (Quiagen) for *E. coli*. The vectors can be introduced into the host cells by a well-known method such as the calcium phosphate method, DEAE dextran method, the method using cationic liposome DOTAP (Boehringer Mannheim) or SuperFect (Quiagen), electroporation, and calcium chloride. A recombinant protein thus obtained can be purified using a conventional technique, for example, the method described in "The Qiaexpressionist handbook, Quiagen, Hilden, Germany".

15 [0027] When the LKB1 protein obtained is used as a therapeutic preparation for diseases caused by mutations in the LKB1 gene, the LKB1 protein can be directly administered, or can be given after formulating by a well-known pharmaceutical process. For example, formulations may be administered in proper combination with a pharmaceutically acceptable carrier or medium, such as sterile water, physiological saline, vegetable oils, surfactants, lipids, dissolving adjuvants, stabilizers, or preservatives. While the dosage for administration differs depending on various factors, such 20 as weight, age, and health conditions, or the method of administration, a person skilled in the art will be able to advantageously select the appropriate dosage. Typically, the dosage is in the range of 0.01 to 1000 mg/kg. Administration can be conducted, for example, orally, intravenously, intramuscularly or subcutaneously.

25 [0028] A person skilled in the art can easily carry out substitution, deletion, addition and/or insertion of amino acids in the amino acid sequence of the LKB1 protein for the purpose of improving the activity and stability of the drug of the present invention, utilizing a well-known method, such as PCR-based site-directed mutagenesis (GIBCO-BRL, Gaithersburg, Maryland), site-directed mutagenesis using oligonucleotides (Kramer, W. and Fritz, HJ (1987) Methods in Enzymol., 154:350-367), the Kunkel's method (Methods Enzymol. 85, 2763-2766 (1988)). A similar altered LKB1 protein can also be used as a therapeutic preparation of the present invention.

30 [0029] Another embodiment of a therapeutic preparation for diseases caused by mutations in the LKB1 gene, the therapeutic preparation comprises a compound, which enhances the activity of the LKB1 protein, as an active ingredient. The LKB1 gene encodes a serine threonine kinase that shows as high as 82% homology with XEEK1 serine threonine kinase from Xenopus. A collapse of the serine threonine kinase activity of the LKB1 protein is closely associated with the emergence of diseases resulting from mutations in the LKB1 gene. Therefore, it is envisaged that enhancement of the said serine threonine kinase activity will serve to treat diseases caused by mutations in the LKB1 gene.

35 [0030] A screening method for a compound that enhances the activity of the LKB1 protein is as follows. For example, LKB1 proteins expressed in *E.coli* as a fusion protein with GST, or those expressed in mammalian or insect cells, are used to determine kinase activities of these proteins in the presence of the test compound, to select a compound that enhances the activity of the LKB1 protein.

40 [0031] More specifically, for example, phosphorylation activity of a substrate protein for the LKB1 protein, or auto-phosphorylation activity of the LKB1 protein may be determined by measuring the transfer of ^{32}P from [γ - ^{32}P]ATP to the substrate in an appropriate reaction solution (e.g. 50 mM Tris-HCl, pH 7.2, 1 mM dithiothreitol (DTT), 10 mM MgCl₂, 10 mM MnCl₂, and so on), using a device, such as a liquid scintillation counter, and thus a compound which enhances the activity of LIB1 protein can be isolated by selecting a compound that increase the ^{32}P transfer level. Like the LKB1 protein used as therapeutic preparation as described above, the isolated compound may be formulated using well-known 45 pharmaceutical processes to be administered for treatment of a disease. Typically, the dosage is in the range of 0.01 to 1000 mg/kg.

45 [0032] In addition to the methods as described above, a method utilizing the regions regulating the LKB1 gene expression, or a factor binding to the gene can be used for treatment of the diseases caused by mutations in the LKB1 gene. The present invention has revealed the structure of the LKB1 gene and the 5' upstream region thereof (SEQ ID: 1). This 5' upstream region may contain the regions regulating the LKB1 gene expression (e.g. promoters and enhancers), and a person skilled in the art could easily specify genetic regions regulating the LKB1 gene expression, using several known methods in combination. A method for specifying the region regulating gene, for example, comprises the following steps: (a) constructing a vector in which a reporter gene is joined to downstream of the 5' upstream region of the LKB1 gene (DNA composed of the whole or a portion of sequence shown in SEQ ID:1); (b) introducing said vector into appropriate cells; and (c) detecting the activity of the reporter gene. Specifically, the upstream region of the LKB1 gene is cleaved into appropriate sized fragments, for example, by various restriction enzymes, and these fragments are integrated into the upstream site of a reporter gene, such as a firefly luciferase, secretory alkali phosphatase, or chloramphenicol acetyltransferase (CAT) gene to construct expression vectors (PicaGeneTM Vector, Wako Pure Chemicals

Industries, Ltd). Subsequently, these expression vectors are introduced into appropriate host cells, such as COS, HEK293, and CHO cells, and then incubated for a certain interval. After the incubation, the intracellular and extracellular reporter gene product expression is separately measured to determine the promoter activity of the individual gene fragment integrated into the vector. Once a gene fragment showing the promoter activity is identified, such a fragment may further be cleaved into smaller fragments and subjected again to the same process as described above to define the active site to a more specified region. To finally confirm the active site, the nucleotide sequence of the region specified as the active site may be altered by, for example, site-directed mutagenesis and the activity is measured. The region regulating the LKB1 gene expression is particularly useful in the gene therapy described above, since it can direct the expression of the LKB1 gene *in vivo*, under natural expression control, when this region is joined to the upstream of the normal LKB1 gene described above and then administered to a patient whose LKB1 gene is mutated.

[0033] In addition, once the promoter region is defined in the upstream of the LKB1 gene, screening for compounds that can regulate the LRB1 gene expression may be easily facilitated by investigating effects on the production of the reporter gene product using reporter gene expression vectors with this site and various compounds. Such screening method comprises the steps of: (a) constructing a vector in which a reporter gene is joined to downstream of the promoter region of the LKB1 gene; (b) introducing said vector into appropriate cells; and (c) detecting the activity of the reporter gene by exposing a test compound to the said cells and/or introducing the compound into the said cells. Test compounds include, but are not limited to, proteins, peptides, synthetic compounds, natural compounds, genes, and gene products and such.

[0034] Screening for compounds that can regulate the LKB1 gene expression may be carried out by exposing a test sample to the promoter region and selecting the compound (e.g. a protein) that binds to said promoter region. For instance, transcriptional regulatory factors which control the LKB1 gene expression and bind to this promoter can be purified using affinity-purification by, creating a synthetic oligo-DNA and such containing the promoter sequence, binding this to a suitable supporting-agent, such as cellulose, and exposing it to a cell-extract and such.

[0035] Additionally, the inventors have revealed that neoplasia, such as polyps, develop as a result of a mutation in the LKB1 gene in the patients with Peutz-Jeghers syndrome. This finding lead to a notion decreasing in the amount or activity of the LKB1 protein can render normal cells temporary cell proliferation activity. Therefore, the artificial reduction in the amount or activity of the LKB1 protein, which is achieved by utilizing anti-sense DNA for the LKB1 gene or the cDNA thereof, or by utilizing a compound which inhibits the activity of the LKB1 gene, will possibly serve to treat the diseases which require fresh cell proliferation, such as wound curing and anagenesis.

Brief Description of the Drawings

[0036]

Figure 1a illustrates the chromosomal organization of the LKB1 gene and the adjacent regions together with the restriction enzyme map, wherein R indicates *Eco*RI site; B, *Bam*HI; S, *Sac*I; K, *Kpn*I; BssH, BssHII. Nine exons of the LKB1 gene were indicated by boxes. Closed and open boxes represent the translated and untranslated regions, respectively. Figure 1b shows a schematic illustration of gene rearrangement found in Peutz-Jeghers patient A. The upper part of the panel shows the organization of the normal-type LKB1 gene; the bottom part shows the organization of the mutant-type gene from Peutz-Jeghers patient A. The orientations and the positions of the primers used in PCR analysis are shown by arrows.

Figure 2 shows a contig of cosmid clones in the region neighboring to the position of microsatellite marker D19S886, and the map of *Eco*RI site in the region. The bottom shows a schematic illustration of positional relationship between the LKB1 gene and microsatellite marker D19S886 in the region of human chromosome 19p13.3; tel denotes the direction to the telomere; cen, the direction to the centromere. The upper part of the panel shows the partially overlapping, arranged cosmid clones.

Figure 3a displays the pedigree of patient A expanding three generations. The symbol in which the right half is filled indicates an affected member. Figure 3b shows the result obtained by long distance PCR with primers, DJ666 and DJ660. An aberrant type of PCR products of 2.5kbp, which is indicated by a filled triangle, is observed only in the affected family members. Figure 3c shows the result obtained by PCR analysis with primers, DJ666 and DJ684. The amplification of the PCR products is observed only in the affected members, which indicates that an inversion exists in the corresponding region.

Figure 4 shows the pattern of agarose gel electrophoresis of LKB1 exons amplified by PCR. Exon Numbers are indicated on the top. MW represents the molecular weight marker.

Figure 5 shows an electrophoretic pattern obtained by PCR-RFLP analysis. The marks, *Ahd*I, *Bsr*BI, *Rsa*I, and *Scal*I on the pattern indicate the samples treated with the corresponding restriction enzymes shown. WT denotes a DNA sample from a healthy normal person; B, Peutz-Jeghers patient B; FA, Peutz-Jeghers patient FA; MA, Peutz-Jeghers patient MA; D, Peutz-Jeghers patient D. MW indicates the molecular weight marker.

Figure 6 shows the autophosphorylation activity of LKB1 protein investigated in the presence of various divalent cations; the protein was immunoprecipitated. The result shows that the autophosphorylation activity of LKB1 (kinase activity) is hardly enhanced by Mg²⁺ but strongly enhanced by Mn²⁺.

Figure 7 shows the autophosphorylation activities of the wild-type LKB1 protein and the various mutants thereof. The top panel displays the autoradiography pattern showing autophosphorylation activity diagnosed by autoradiography; the bottom shows the results of a Western blotting stained with an anti-c-Myc antibody. Each protein is observed to be produced at a similar level.

Figure 8 shows an electrophoretic pattern of a GST-fusion of LKB1-myc protein expressed in *E. coli*, which was analyzed by Western blotting. M indicates the molecular weight marker; 1, a lysate of the *E. coli* cells prior to the induction by IPTG; 2, a lysate of the *E. coli* cells after the induction by IPTG; 3, the GST-fusion of LKB1-myc protein purified with glutathione Sepharose. The filter labeled with "Anti-Myc antibody" was stained using the anti-myc antibody; the one labeled with "Anti-LKB1 antibody" was stained with an affinity-purified anti-LKB1 peptide antibody. Figure 9 shows the result of Western blotting using the respective antibodies. Lane 1 contains a sample lysate from COS7 cells with transfected DNA of pcDNA3 vector alone; lane 2, a lysate from COS7 cells with transfected pcDNA3/LKB1myc; lane 3, a lysate from HeLa S3 cells. The samples were stained with the antibodies indicated at the left and the anti-c-Myc antibody. Peptides used in the pre-incubation treatment are shown on the top.

Figure 10 shows a tissue section of human fetal colon stained using anti-LKB1 P3 antibody. The cytoplasm of the epithelial cells is positive in the stain. The cells, which are assumed to be endocrine cells, are also stained very intensely.

Figure 11 shows a tissue section of human adult pancreas stained with the anti-LKB1 P3 antibody. The islet cells are positive in this staining.

Figure 12 shows a tissue section of human fetal testis stained with the anti-LKB1 P3 antibody. The undeveloped germ cells were stained intensely.

25 Best Mode for Carrying out the Invention

[0037] The present invention will be described further in detail by referring to the examples below, but is not to be construed as being restricted thereto.

30 Example 1. Construction of a cosmid clone contig covering a region on human chromosome 19p13.3

[0038] In order to identify efficiently all the genes located in the region of human chromosome 19p13.3, a contig of contiguous clones (contig of arranged clones) assembled with cosmid clones and other clones was constructed. Suitable cosmid clones were selected from a group of clones mapped in this region by FISH, having short and different overlapping regions; and gaps between the clones were successively filled with clones obtained by screening cosmid, phosmid and BAC libraries (cosmid walking, chromosome walking). A high-resolution physical map was, thus, prepared by constructing a contig of the contiguous clones covering a 1.5Mbp region on chromosome 19pter.

[0039] Specifically, the contig was constructed as described below. A short contig of cosmid clones covering a region on chromosome 19p13.3, which was mapped and aligned previously by FISH (Ashworth, L. K. et al. An integrated metric physical map of human chromosome 19. *Nature Genet.* 11, 422-427 (1995)), was further extended using genomic clones obtained from chromosome 19-specific cosmid libraries with Lawrist5 vector as well as Lawrist16 vector, a chromosome 19-specific phosmid library with pBeloBac11 vector, and an entire human genome cosmid library (Stratagene) as well as an entire human genome BAC library (Research Genetics). The cosmid walking was started from the ends of two contigs each containing the PRNT3 gene locus (Zimmer, M. et al. Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. *Proc. Natl. Acad. Sci. U.S.A.* 89, 8215-8219 (1992)) or the GZMM gene locus (Pilat, D. et al. The human Met-ase gene (GZMM): structure, sequence and close physical linkage to the serine protease gene cluster on 19p13.3. *Genomics*, 24, 445-450 (1994)) on 19p13.3. Specifically, overlapping clones were successively obtained by screening using the EcoRI fragments derived from the ends of the contigs as probes; the high-density filters of the cosmid and phosmid libraries were treated with Cot1 DNA (New England Biolabs) for background reduction. In some cases, nucleotide sequences of the insert ends were determined directly using the cosmid clones as sequence templates; the primers used were Lawrist vector-specific primers, DJ180 (SEQ ID NO: 35/CGACTCACTATAGGGAGACCC) and DJ181 (SEQ ID NO: 36/CCTCGAGAATTACCCTCACTAA). The sequences determined were utilized: (i) to search the databases for the identification of novel genes exhibiting significant homologies to known genes; (ii) to prepare STS (Sequence Tagged Site) which is used for further experiments of chromosome walking. Thus, the contig was assembled from cosmid clones covering a 1.5Mbp region near the telomere on chromosome 19. Restriction sites of BamHI, BssHII, EcoRI, HindIII, KpnI, and SacI were mapped on the cosmid clones, to prepare a restriction enzyme map of the region. More specifically, the map construction was carried out by the following procedures: the cosmid DNAs were lin-

EP 1 036 844 A1

earized by treatment with lambda terminase and by partial digestion using restriction enzymes; the cos sites of the DNAs were labeled, and subsequently digested with restriction enzymes; the map was made based on the length of each restriction fragment (cos-site labeling method; Rackwitz, H. R., et al. Analysis of cosmids using linearization by phage lambda terminase. *Gene* 40, 259-266 (1985)).

5 Example 2. Identification of genes mapped on the cosmid clone contig on 19p3.3

[0040] Previously, by radiation hybrid mapping method, 91 clones of EST (Expressed Sequence Tag) have been mapped in a region more proximal to the telomere than the genetic marker, D19S216, on 19p3.3. Clones of EST overlapping one another were removed by analyzing the sequences using a software program, UNIGENE, (<http://www.ncbi.nlm.nih.gov/UniGene/index.html>), and as a consequence, 60 clones of EST were finally identified to be derived from independent genes. Primer sets for amplifying the respective ESTs were purchased from Research Genetics; the cosmid clones belonging to the previously constructed contig on 19p3.3 were categorized into four non-overlapping groups; then the locations of the respective genes were assigned on the contig by PCR screening. When an EST gave the positive signal, then the databases were searched for other overlapping ESTs to extend the sequence of the EST. Complementary DNAs corresponding to the respective positive ESTs were purchased from Research Genetics; using the inserts of the cDNAs as probes, EcoRI-digested cosmid clones were analyzed by Southern hybridization, to determine the accurate positions of the respective genes in the contig.

[0041] The accurate position of genetic marker D19S886 (GenBank accession number: Z52881) was also determined in this cosmid clone contig. Specifically, a DNA fragment containing the marker sequence was prepared from the human total DNA by PCR amplification using the sense primer (SEQ ID NO: 37/TGGATCTACACTCCGGC) and the antisense primer (SEQ ID NO: 38/ATTTTACTGGCTGGCACTTG); the cosmid clone, R32184, was digested with EcoRI, SacI, BamHI, or BssHII, and then the digest was subjected to Southern-blot analysis using the DNA fragment as a probe, to determine the accurate position of the marker on the EcoRI map.

[0042] Moreover, mouse genes mapped previously in a region of mouse chromosome 10, which corresponds to human 19p, were mapped on this contig by similar procedures. Furthermore, new genes contained in this contig were identified by searching databases such as LLNL database [<http://www-bio.llnl.gov>] with the sequences of the cosmid ends.

30 Example 3. Identification of a candidate region containing the Peutz-Jeghers gene

[0043] Earlier linkage studies have reported that a candidate region for the Peutz-Jeghers gene may be located more proximally to the telomere than markers D19S878 and D19S565; however there was no reported marker located on the telomere side of these markers at all, and accordingly the candidate region was assumed to span over a genomic region of as long as approximately 2Mb or more on the telomere side of the markers. Nonetheless, there was the possibility that the mutant gene was located very near this marker, considering the close linkage of D19S886 marker and the Peutz-Jeghers gene locus. Thus, the accurate position of marker D19S886 was first determined in the cosmid contig as described above, and then the neighboring genes were diagnosed. The result showed that there were 21 genes within the region of 400kbp neighboring to marker D19S886. Candidates for the causative gene of Peutz-Jeghers syndrome were selected from the newly identified genes, based on a wide variety of biological information such as information obtained by the analyses of the counterpart genes of other species. The samples of chromosomal DNA prepared from Peutz-Jeghers patients were diagnosed for nucleotide mutations within the respective genes selected.

45 Example 4. Identification of the LKB1 gene and the analysis of genomic organization thereof

[0044] The GenBank database was searched for the sequences exhibiting homologies to cosmid clone R29114 at its end on the telomere side, which was contained in the contig spanning over a region on 19p3.3; the result showed that the cosmid end shared a short sequence of 32bp with a cDNA (GenBank accession number: U63333) encoding a novel human serine-threonine protein kinase (LKB1). The cosmid clone was directly sequenced using primers, DJ649 (SEQ ID NO: 24) corresponding to the 5' end of the LKB1 cDNA sequence and DJ650 (SEQ ID NO: 29) corresponding to the 3' end; clone R29114 and the adjacent clone R26552 contained the LKB1 gene, and thus it was clarified that the LKB1 gene was located in this region. For the determination of the entire exon-intron organization of the LKB1 gene and for further analyses in detail, PCR primers and sequence primers (shown below; Tables 1 and 2) were designed, based on the LKB1 cDNA sequence (1302bp). Sequences of the respective gene segments were determined by direct sequencing of the PCR products amplified from the cosmid DNAs. The sequences obtained were compared with the LKB1 cDNA sequence to identify positions of the exons and the splice junctions of all the introns. Each exon position on the restriction map was determined by comparing the positions of restriction sites in the genomic sequence and by comparing the distances, estimated by long distance PCR, between the respective segments of the gene (Figure 1a).

EP 1 036 844 A1

Nucleotide sequence was determined by bi-directional sequencing in almost all the regions except for prominently long introns 1 and 8.

[0045] The result showed that the LKB1 gene spanning over 23kb or more was split into 9 coding exons and a non-coding exon. Moreover, the gene was presumed to be transcribed toward the direction from the telomere to the centromere (Figure 2); interestingly, the splice junction of intron 2 was revealed to violate the GT/AG rule characteristic of ordinary intron-exon junctions. The sequence of intron 2 starts with "ATATCCCTT" at the 5' end and terminates with "CCCAC"; the "TCCTTAAC" motif is located 15bp upstream of exon 3. These three sequence elements have close similarities to those of the eukaryotic intron which has been recently reported to be as a very rare intron. Introns with this sequence pattern are spliced in a U12 snRNA-dependent manner, which is not the general way of splicing.

10

Example 5. Analysis of mutations in patients affected with Peutz-Jeghers syndrome

[0046] Sequences of the primers used for the mutation analysis of the patients affected with Peutz-Jeghers syndrome are shown in table 1 below.

15

Table 1

DJ705	5'-GGGAATTCGGAACACAAGGAAG-3'	(SEQ ID NO: 23/exon 1)
DJ649	5'-ATGGAGGTGGTGGACCCGC-3'	(SEQ ID NO: 24/exon 1)
DJ659	5'-GTTACGGCACAAAAATGTCATCCA-3'	(SEQ ID NO: 25/exon 2)
DJ666	5'-GGTGATGGAGTACTGCGTGTG-3'	(SEQ ID NO: 26/exon 3)
DJ684	5'-ACATCGGGAAAGGGGAGCTACG-3'	(SEQ ID NO: 27/exon 6)
DJ660	5'-CCGGGCACCGTGAAGTCTG-3'	(SEQ ID NO: 28/exon 8)
DJ650	5'-TCACTGCTGCTTGCAGGCC-3'	(SEQ ID NO: 29/exon 9)
DJ717	5'-GCAGGCAGGCCAGCCTCA-3'	(SEQ ID NO: 30/exon 9)

30

[0047] Mutation analysis was carried out using DNA samples from five unrelated patients affected with Peutz-Jeghers syndrome (patients A, B, D, MA and FA). The deletion and rearrangement of the gene were screened by long distance PCR using the primer sets, DJ659 and DJ660, and DJ666 and DJ660.

[0048] All the DNA samples derived from the patients and healthy normal persons as controls gave the products of 3.9kbp in the PCR amplification with the primer set of DJ666 and DJ660. However, not only the 3.9kbp products but also the products of 2.5kbp were found in the sample of Peutz-Jeghers patient A (Figure 3b). The shorter DNA fragment was subcloned, sequenced and then compared with the chromosomal DNA sequence of the normal counterpart; the result showed that the LKB1 gene was complicatedly rearranged in the chromosome of this patient (Figure 1b). Specifically, the PCR products of 2.5kbp had two deletion mutations; one is a deletion of a 1286bp segment located between intron 3 and intron 5, and the other is a deletion of an 81bp segment located inside intron 7. The longer deletion contains exons 4 and 5. In addition to this, an inversion was found in the central region containing exons 6 and 7. The existence of the inversion was confirmed by PCR analysis using sense primers, DJ666 and DJ684, which were specific to exon 3 and exon 6, respectively. Both of these primers correspond to the sense chain, and therefore PCR products are given only when the inversion exists. The analysis has revealed that the inversion is carried by all the affected family members, including patient A, for two generations. On the other hand, this mutation was found neither in the healthy members of the same family nor in unrelated healthy normal persons used as controls (Figures 3a and 3c).

[0049] The complicated LKB1 mutation was analyzed at the level of transcripts by RT-PCR using RNA prepared from the cells of peripheral blood of patient A. The RNA was isolated using an RNA Isolation Kit (Qiagen) and reverse-transcribed into cDNA using Superscript (GIBCO-BRL, Life Technologies). Two distinct PCR products of 730bp and 270bp were given by PCR using a primer set of DJ660 and DJ666. There is a length difference of about 460bp between the two types of the PCR products; the length agrees well with the length between exon 4 to exon 7 in the transcript, suggesting the production of the transcript from which the segment of exons 4 to 7 has been removed by splicing, and which was presumed to be caused by the complicated mutation. The aberrant splicing event, in which exon 3 directly links to exon 8, does not result in frameshift, but the resulting transcript is assumed to encode an aberrant protein consisting of 281 amino acids in which the C-terminal half of the catalytic domain is missing.

[0050] The aberrant PCR products were not observed in any of patients B, D, MA, and FA. Eight sets of primers were designed for the screening of point mutations in the LKB1 gene (Table 2); the respective exons were amplified independently and then directly sequenced (Figure 4).

EP 1 036 844 A1

Table 2

DJ698	5'-GGTCCCCGAGGACGAAGTTGA-3'	(SEQ ID NO:7/exon 1 sense)
DJ673	5'-ACCATCAGCACCGTGACTGG-3'	(SEQ ID NO:8/exon 1 antisense)
DJ703	5'-TCGCCGGCCGATGACAGA-3'	(SEQ ID NO:9/exon 2 sense)
DJ674	5'-AAGGAGACGGAAAGAGGGAGCAG-3'	(SEQ ID NO:10/exon 2 antisense)
DJ690	5'-GAGGAGGGGCAAGGTGGGT-3'	(SEQ ID NO:11/exon 3 sense)
DJ680	5'-GTGTGGCCTCACGGAAAGGAG-3'	(SEQ ID NO:12/exon 3 antisense)
DJ692	5'-AGCTGGGCCTGTGGTGGT-3'	(SEQ ID NO:13/exon 4-5 sense)
DJ694	5'-CAGAGGCCCTCGGAGTG TG-3'	(SEQ ID NO:14/exon 4-5 antisense)
DJ695	5'-GCCTCTGTCCCTGGGGTAGA-3'	(SEQ ID NO:15/exon 6 sense)
DJ693	5'-TCAGTCCTCTCAATGCCTGCTG-3'	(SEQ ID NO:16/exon 6 antisense)
DJ696	5'-GCGGGGTCCCCCTTAGGAG-3'	(SEQ ID NO:17/exon 7 sense)
DJ697	5'-CTAGCGCCGCTAACAG-3'	(SEQ ID NO:18/exon 7 antisense)
DJ675	5'-GGAGCTGGGCGGAAAATCGGA-3'	(SEQ ID NO:19/exon 8 sense)
DJ702	5'-TGCTCCCGTGGGACATCCTG-3'	(SEQ ID NO:20/exon 8 antisense)
DJ676	5'-GTAAGTGCCTCCCCGTGGTG-3'	(SEQ ID NO:21/exon 9 sense)
DJ677	5'-GTGGCATCCAGGCCTGTCC-3'	(SEQ ID NO:22/exon 9 antisense)

[0051] Since the intron between exon 4 and exon 5 is short, the exons were amplified together at the same time. The result showed that all the patients carry mutations in one of the two alleles of the LKB gene. The result is shown in Table 3. Codon numbers in the table indicate the last wild-type codon. Restriction enzyme sites were diagnosed for the presence of mutations in the PCR products of the Peutz-Jeghers patients as well as healthy normal persons. The symbols, + and -, accompanying the names of restriction enzyme indicate the presence and absence of the site, respectively. Nucleotides of LKB1 genes derived from patients B, MA and FA have been numbered on referring to nucleotide numbers assigned in the LKB1 cDNA sequence deposited in GenBank (accession number: U63333). Nucleotide numbers used in the LKB1 sequence from patient D are indicated on referring to those of the LKB1 gene sequence deposited in GenBank (accession number: AF032985).

Table 3

Patient	Mutation type	Mutation position	Codon	Restriction site	Possible influence
A	inversion/deletion	exon 4-7	155		<ul style="list-style-type: none"> • deletion of codons 156-307
D	G2412A	intron 3	156	+Scal	<ul style="list-style-type: none"> • deletion of splice acceptor site • exon 4 skipping; frameshift • premature termination at codon 242
B	deletion of GGTC at nucleotide position 716	exon 5	240	-AhdI	<ul style="list-style-type: none"> • premature termination at codon 285; frameshift
MA	C759A	exon 6	252	-RsaI	<ul style="list-style-type: none"> • Tyr253 (TAC) → Stop codon (TAA)
FA	deletion of G at nucleotide position 843	exon 6	280	-BsrBI	<ul style="list-style-type: none"> • frameshift; premature termination at codon 286

[0052] In patient MA, C is substituted for A at nucleotide position 759 (in exon 6), and as a result, TAC codon of tyrosine is altered to a stop codon, TAA, at amino acid position 253. It was revealed that, in patient B, four base pairs from nucleotide position 717 to 720 (in exon 5) were deleted; the deletion results in the generation of a stop codon at the position 135bp downstream from the codon for tryptophan at amino acid position 239. In patient D, the di-nucleotide AG to be conserved strictly at the splice acceptor site located at the 3'end of intron 3 was found to be altered to AA. When exon 4 is skipped and as a result exon 3 links to exon 5, a frameshift occurs immediately behind amino acid position 155 and the protein sequence terminates at amino acid 241. It was found that, in patient FA, nucleotide G at nucleotide position 843 (exon 6) was deleted, which caused a frameshift and the generation of a stop codon, TGA, at nucleotide 857.

[0053] All the mutations found in the LKB1 gene of the five patients affected with Peutz-Jeghers syndrome result in loss of the indispensable part in the kinase domain, and as a consequence the conformation is presumed to be destroyed in the mutant LKB1 proteins. In addition, the C-terminal amino acids, which were assumed to constitute the regulation domain in LKB1 protein, were missing in the four of these patients. These mutations in the LKB1 gene were considered to give rise to the loss of kinase activity in the LKB1 proteins as mutant gene products, and the signal transduction pathway in which LKB1 was involved was blocked as a consequence.

[0054] The genomic organization of the LKB1 gene was similarly investigated in a Japanese patient affected with polyposis who was suspected of Peutz-Jeghers syndrome (SK1). The genomic DNA was extracted from the peripheral blood of the patient using a QIAamp Blood kit (Qiagen), and the LKB1 gene was amplified by PCR using the DNA as a template and using the primers indicated in Table 2. The result of direct sequencing analysis of the PCR products showed that there was a single-base (C) deletion (the C is the third nucleotide of codon "GAC" corresponding to Asp at amino acid position 207) in the coding region within exon 5. The mutation results in a frameshift on the C-terminal side of Asp 207, which perhaps generates a truncated protein without the kinase activity as a result.

[0055] The PCR amplification of the LKB1 gene derived from the DNA sample was performed basically under the following conditions: the reaction solution, of which total volume was 50 µl, contained 100 ng of chromosomal DNA (template DNA), 50pmol of primer, PCR buffer J (Invitrogen), 2.5 units of AmpliTaq (Perkin Elmer), and 2.5 µl of DMSO, or the solution contained 100 ng of chromosomal DNA (template DNA), 20pmol of primer, 5 µl of 10x TaKaRa Tag buffer (TaKaRa), 4 µl of 2.5mM dNTPs (TaKaRa), 0.4 µl of TaKaRa Tag DNA polymerase (TaKaRa), and 0.4 µl of Taqstart™ Antibody (CLONTECH); the reaction profile was: pre-heat at 94°C for 2 to 4 minutes; 35 cycles of denaturation at 94°C for 30 to 45 seconds, annealing at 58°C or 62°C for 30 seconds and extension at 72°C for 45 seconds; and the final extension at 72°C for 3 minutes. The resulting PCR products were purified using a QIAquick Gel Extraction kit (Qiagen) after agarose gel electrophoresis, or purified from the PCR reaction solution using a QIAquick Nucleotide Removal kit (Qiagen); using the purified PCR products as a template, direct sequencing was performed bidirectionally. A Rhodamine terminator cycle sequencing kit (Applied Biosystems) was used in the sequencing.

[0056] In order to verify that the mutations found were not caused by artifacts in PCR amplification or in sequencing, DNAs covering the regions containing the mutations were amplified by PCR under the conditions described above, the resulting PCR products were digested with restriction enzymes selected for the respective mutations, and then the lengths of the fragments obtained by the digestion were diagnosed for the mutation sites (PCR-RFLP analysis). Specifically, a 20 µl reaction solution consisting of 5 µl of PCR products, 4 units of restriction enzyme (*Ahd*I, *Bsr*B I, *Rsa*I or *Scal*I) and 2 µl of restriction enzyme buffer was incubated at 37°C for 1.5 hours; the resulting lengths of the DNA fragments were analyzed by agarose electrophoresis.

[0057] When the DNA samples from 50 healthy persons were diagnosed by the same analysis, the mutations were not observed in these samples at all; thus the results showed that the mutations were specific to patients with Peutz-Jeghers syndrome (Figure 5).

45 Example 6. Construction of plasmid DNAs for the expression of the LKB1 gene in *E. coli* and mammalian cells

[0058] A DNA fragment encoding the entire LKB1 amino acid sequence with a c-Myc epitope sequence (SEQ ID NO: 41/Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu) as a C-terminal tag was amplified by PCR using the LKB1 cDNA clone as a template and using LK E1 primer (SEQ ID NO: 39/5'-gat gaa ttc ggg tcc agc atg gag gtg gtg gac-3') and LK E2 primer (SEQ ID NO: 40/5'-gat gaa ttc tta gag gtc ttc tga gat gag ctt ctg ctc ctg ctg ctt gca ggc cga-3'); the PCR products were digested at the EcoRI sites located within the primer sequences; the EcoRI fragment was inserted into pcDNA3 vector (Invitrogen) at the EcoRI site for the expression in mammalian cells or into pGEX-5X-1 vector (Pharmacia) at the site for the expression in *E. coli*. The cloned DNAs were diagnosed by sequencing not to have any sequence variations as artifacts caused by PCR amplification; and such clones were selected and used for expression experiments.

[0059] *In vitro* mutagenesis was carried out using pcDNA3/LKB1myc as a template and using GeneEditor™ (Promega), to prepare expression plasmid DNAs with the mutations corresponding to the amino acid substitutions found in the Peutz-Jeghers patients. Specifically, the expression plasmid DNA (pcDNA3/LKB1 D176Nmyc) for D176N

EP 1 036 844 A1

mutation (the abbreviation means the substitution mutation from Asp to Asn at amino acid 176; the mutations shown below are also abbreviated in the same way) was constructed by introducing the mutation using LK D176N primer (SEQ ID NO: 45/5'-att gtg cac aag aac atc aag ccg ggg-3'); the plasmid for mutation W308C (pcDNA3/LKB1 W308Cmyc), LK W308C primer (SEQ ID NO: 46/5'-ccg cag cac agc tgc ttc ccg aag aaa-3'); the plasmid for L67P mutation (pcDNA3/LKB1 L67Pmyc), LK L67P primer (SEQ ID NO: 47/5'-gtg aag gag gat ccg gac tcg gag acg-3'); plasmid DNA for K781 mutation (pcDNA3/LKB1 K781mcy), LK K11 primer (SEQ ID NO: 48/5'-agg agg gcc gtc atc atc ctc aag aag-3'). The DNA strand was newly synthesized by annealing the single-stranded template DNA of the plasmid with two primers; one was the primer for the introduction of the mutation, and the other was a selection primer (for bottom strand) appended to the kit. The prepared DNA was introduced into *E. coli* cells; clones resistant to the antibiotic, Gene Editor TM, were selected to obtain the cells containing the plasmids with the mutation. The plasmids, which were verified to have the mutation by sequencing, were used for expression experiments.

[0060] The C-terminal end of LKB1 protein can be tagged with an epitope peptide (SEQ ID NO: 44/NH₂-YPYDVP-DYASL-COOH) recognized by anti-HA antibody or tagged with a sequence of consecutive 6 histidine (H) residues (histidine hexamer), by introducing, into a variety of vectors, the DNA fragments prepared by PCR using LK E4 primer (SEQ ID NO: 42/5'-gat ggg ccc tta cag gga ggc ata gtc agg cac atc ata tgg gta ctg ctg ctt gca ggc cga-3') or LK E5 primer (SEQ ID NO: 43/5'-gat gaa ttc tta gtg atg gtg atg gtg atg ctg ctg ctt gca ggc cga-3'), respectively, instead of LK E2 primer. By utilizing the tagged constructions, LKB1 protein can be detected by the methods using with anti-HA antibody or anti-histidine hexamer-antibody, or can be purified by an affinity-purification method with anti-HA antibody or the nickel column.

Example 7. Gene expression of LKB1 in mammalian cell and the kinase activity assay

[0061] About 10 µg of the expression plasmid DNAs, including the plasmid DNA prepared for LKB1 expression (pcDNA3/LKB1myc), was introduced into COS7 cells (by transfection) by the method using SuperFect (Qiagen). Specifically, after about 10^6 COS7 cells were placed in a 10cm dish and cultured overnight, a mixture consisting of 10 µg of plasmid DNA and 60 µl of SuperFect was added thereto and then cultured for about 3 hours. Subsequently, the cells were further cultured in a fresh medium for 1 to 2 days, and then harvested by using a trypsin-EDTA solution. The cells were suspended in an NP40 kinase lysis buffer (10mM Tris-hydrochloride (pH7.8), 1% NP40, 0.15M sodium chloride, 1mM EDTA, 50mM sodium fluoride, 5mM sodium pyrophosphate, 10 µg/ml aprotinin, and 1mM PMSF); the proteins were solubilized by stirring the suspension at 4°C for 30 minutes. Protein A/G plus agarose (Santa Cruz) was added to the cell lysate obtained, and the mixture was stirred for 30 minutes to remove non-specific proteins adsorbed by the beads. Anti-c-Myc antibody A14 (Santa Cruz) was added to the mixture and then the mixture was left to stand at 4°C for 1 hour; protein A/G plus agarose (Santa Cruz) was added thereto, and the mixture was allowed to stand for another 1 hour. The resultant immune-complex was precipitated from the mixture by centrifugation, washed several times with the NP40 kinase lysis buffer, a buffer containing 1M sodium chloride and a solution of 50mM Tris-hydrochloride (pH7.8); the precipitate was used to assay the kinase activity.

[0062] The kinase assay was performed in the reaction system of a 50 μ l solution containing 50mM Tris-hydrochloride (pH7.8), 1mM DTT, 10mM divalent cation (Mn, etc.), and 10 μ Ci of [γ -³²P] ATP. The immunoprecipitate was incubated in the kinase assay solution at 37°C for 30 minutes and then the reaction was stopped by adding the SDS-PAGE sample buffer and boiling; the sample was subjected to SDS-PAGE. The gel was fixed with a methanol/acetic acid solution, dried and then analyzed by a BAS200 image-analyzer (FujiFilm). The kinase activity of LKB1 assayed was evaluated as the autophosphorylation activity. The protein expressed was detected by SDS-PAGE followed by Western blotting using anti-c-Myc antibody A14.

[0063] The divalent cation-dependency in the kinase activity was first diagnosed, and the result showed that the kinase activity was hardly enhanced by Mg^{2+} but enhanced intensely by Mn^{2+} (Figure 6). The kinase activity was diagnosed in the mutant proteins containing amino acids substituted in the Peutz-Jeghers patients; none of the mutant proteins exhibited the kinase activity (Figure 7). These findings strongly suggest that LKB1 kinase loses its activity in Peutz-Jeghers patients and which becomes the cause of the disease.

50 Example 8. Expression of LKB1 protein in *E. coli*

[0064] Plasmid pGEX/LKB1myc was introduced into *E. coli* strain DH5 α , and a single-colony was selected. The *E. coli* cells were cultured in 10 ml of 2xYT medium at 37°C overnight; an aliquot taken from the culture was diluted 100 times by fresh 2xYT medium; the *E. coli* cells were further cultured at 37°C until the OD value of the medium measured at 600nm reached 0.6. IPTG (isopropyl β -D(-)-thiogalactopyranoside) was then added to the culture at a final concentration of 0.1mM, and the culture was prolonged for another several hours. The bacterial cells were collected by centrifugation, suspended in PBS containing 1% TritonX-100 and 1% Tween 20 and lysed by sonication to solubilize their proteins. LKB1 protein expressed as a fusion protein with glutathione-S-transferase (GST) was purified from the solu-

bilized sample by an affinity purification method using glutathione Sepharose 4B (Pharmacia). The LKB1 protein expressed in *E. coli* was also detectable by Western blotting using anti-c-Myc antibody A14 (Figure 8).

Example 9. Preparation of antibody against LKB1 protein and the use thereof

5 [0065] Two peptides were synthesized (Sawady Technology) based on the amino acid sequences of the N-terminal end and the C-terminal end of LKB1 protein, and the sequences are as follows: NH₂-CHRIDSTEVIYQPRRKRAKL-COOH (SEQ ID NO: 34) of LKB1 P6 peptide (amino acid 27-45) and NH₂-CLSTKSRAEGRAPNPARKA-COOH (SEQ ID NO: 31) of LKB1 P3 peptide (amino acid 400-417). The respective peptides were conjugated at the N-terminal 10 cysteine with keyhole limpet hemocyanin (KLH) by a method using m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) (Sawady Technology). The conjugated peptides were given to rabbits several times as antigens for immunization. The specific antibodies reacting to these peptides were purified from the antiserum by affinity columns prepared using cellulofine (Seikagaku Co.) to which the peptides were linked.

15 [0066] The results of Western blotting with these antibodies (anti-LKB1P6 antibody and anti-LKB1P3 antibody recognizing the N-terminal and C-terminal ends of LKB1 protein, respectively) are shown in Figure 9. The results showed that the band (indicated by arrow) of about 55 kDa corresponding to the LKB1 protein expressed in COS7 cells was detectable by each antibody. Because the positive immunoreaction was blocked when the antibody was pre-incubated with a large excess of the corresponding peptide antigen, the reaction was considered to be specific to the epitope. In addition, no cross-reaction was seen with the lysate from HeLa S3 cells; the cells express no LKB1 protein; and thus it 20 is safe to conclude that LKB1 protein can be detected with high specificity by these antibodies. It was also shown that the LKB1 protein expressed as a GST fusion protein in *E. coli* was detectable with anti-LKB1 P3 antibody (Figure 8).

25 [0067] The results of immuno-staining of human tissue sections with the antibodies are shown in Figures 10, 11, and 12. Figure 10 shows an immuno-stained tissue section of human fetal colon. The cytoplasm of the epithelial cells was positively stained. The cells, which are assumed to be endocrine cells, are also stained very intensely. Figure 11 shows an immuno-stained tissue section of human adult pancreas. The islet cells are stained positively. Figure 12 shows an immuno-stained tissue section of human fetal testis. The undeveloped germ cells are stained intensely. The immuno-staining patterns shown were obtained with anti-LKB1 P3 antibody; similar results were also obtained with anti-LKB1 P6 antibody. The positive immunoreactions shown were blocked when the antibody was pre-incubated with the corresponding peptide antigen, so that the staining was considered to be specific.

30 Industrial Applicability

[0068] The present invention revealed that Peutz-Jeghers syndrome was caused by the mutations in the LKB1 gene. The invention made it possible to diagnose and treat the diseases caused by the mutations in the LKB1 gene, 35 such as Peutz-Jeghers syndrome, by utilizing the LKB1 gene, primers or probes designed based on the sequence thereof, LKB1 protein and the antibodies thereto.

40

45

50

55

SEQUENCE LISTING

5 <110> CHUGAI RESEARCH INSTITUTE FOR MOLECULAR MEDICINE, INC.

10 <120> DIAGNOSTIC METHOD, DIAGNOSTIC REAGENT AND THERAPEUTIC PREPARATION
FOR DISEASES CAUSED BY VARIATION IN LKB1 GENE

15 <130> C2-909DP1PCT

20 <150> JP 1997-344256
JP 1998-280357

25 <151> 1997-11-27
1998-10-01

30 <160> 48

35 <210> 1

<211> 3765

<212> DNA

<213> Homo sapiens

40 <400> 1

gcccactgct ttatgcggcc gtttcatttg atgtaatccg agcccggtgc gaagccgaag 60

caggtggatc acctgagggtt aggagttcgg gaccagcctg aacaatatgg taaaaccctg 120

tctctattga aaatccaaaa attatccagc catgggtgt tatgcctgta gtcccagcta 180

ctccagaggc ttagacagga gaattgcttg aatctggaa gcagaggttg cagtgaacca 240

agatcatgcc attgcactcc agccgggca acagagcgag actccgtctc aaaaaaaaaa 300

aaagagagtc agtgtggagg gaagtgtctc ttttgggtcc gggtgctctg tgggactctg 360

aggaaaagct cgcaccaggt agatgctgtt ctgtccccat ggttaaagga caccccaaca 420

aaccgaggag caaatgtcc tcgtatgcc tcttcgcgca gacctgccag gaagagcaca 480

agaagaaaaca cccggactct tctgtcaatt tcgtgaaatt ctccaagaag tttttggaga 540

gatggaagac cacgtctgca aaggagaagt gaagttgaa gagaaggcaa aaagtgacaa 600

EP 1 036 844 A1

	agctcgctgt gacaggaga ttaaaaatta cattcctccg aaatgttaga aaggtaaga	660
5	aaggaaagaa aaaggatgc aatgttcata gaaggccacc atctgccttc ttctgtttt	720
	gctctgaaca tcgccccaaag atcaaaagtg gacacccagg cctatttgc gtggaaactg	780
10	caaagaaact gggtaaatg tggctgggc agtcagccaa agataaacaaccatatgagc	840
	agaaagcagt taagctacag gagagatatg aaaagggtat tgctgcataat cgtgctaagg	900
15	gcaaaagtga agcaggaaag aaggctcaa agaagaacaaccagaagat gaggaggagg	960
	aggaggagaa agaagatgaa gatgaggagg aagagggtga agatgttggaa taaatggcta	1020
20	tcctttatg atgcctgtgc agtggcttg tttgtttaag aatgttgaatt ctgttacagc	1080
	tcatgtttag cticagtata aaactgtaca aattttcgta tagcttataa gattcttgt	1140
25	acagaaaata cttttttttt cttttttttt tttttagaca gagtttcgtt cttgttgcct	1200
	aggctggagt gcaatggcgatctcggtt caccgcacc tccgcctccc gggcctgg	1260
	tcaaggcgtt ctctgcctc agcccttgcgtt gtagctggat ttacaggcac atgccaccac	1320
30	gctcgtttaa tttttgtatt ttttagtagat atgggtttt accatgttgg ccaggctgt	1380
	ttcaaaactcc tgacctcgatccgcctgc ttccgcctcc caaaataactg ggattacagg	1440
35	tgtgagccac cgccaccctgc ctaatgtccc taaatattta atggttttttaaaaatttat	1500
	tgtgtatggc agcacagcac actttaggat attagttatca acagtttacatc ttgcgttttt	1560
40	taagatgttgc catttttaa cattttgtaa taaaattatg cgtatcaaaaaa aaacaaagaa	1620
	attccgtgtt tagttcacac tcacagcaca tctccgttcca ggcactttagt agaatgacta	1680
45	ggaggggttc ttggaggagg tggcttttgc acggagaatc catcttcaag gattctgtct	1740
	gtaatggtca ccaagtattt cctgagtccat tccatgtgtt cctgcgttcc tctgaagggg	1800
50	cgtggaccc accgatgcca attatccagc attatcttca gatttcaaga agttgggttgc	1860
	tgagccagca atcagtacag aaaagagata ccaaaaataag tttagttgg ggagtgttcc	1920

EP 1 036 844 A1

	ttcaacttca gttttctgga agagatctt ttttttttt tgagacagag ttgcgtctt	1980
5	attgccaag ctggagtgcg gtggcacat ctcggctcac cgcaacctcc tcctccggg	2040
	ttcaagcgat ttcctccct cagcctctg agtagctggg attacagaca tgcacctgt	2100
10	atttctacta aaaatacata aattagccgg gcgtggtggc gcacgcctgt aatctcagct	2160
	actggggagg ctgaggcagg agaatcgctt gaaaccagga ggcggagatt gtaccaagat	2220
15	agtttgttcc agctaaacaa cctggcgcta gtgcaggaaa aggtggaagg cacgggcta	2280
	gcacaggagg gttcaatatt ttcaaccta tcaagccata ttttggcaac tcttggttt	2340
20	cacgagaagc ccccgtggg ctgtcccag cgctgtcctg aggtttcccc catgagtcc	2400
	gatagggcag aggccgcct gagcgtttct cttcccttg gtccaaagagt ggctaaaaag	2460
25	aaggattttt gactggaatt ggccacttg tgttactttt tgacccttga cctcgcccc	2520
	aagggggatg cgggggaggg gctctggtag gggtgcccc gtccttcca ggtccgcaag	2580
30	cccaggttcc cggccacccgg gtcagccca ccctgccc gttcagggag gccgttggca	2640
	cccggtaccc acgacccct tcccgagccc caccgaggcc acagccgtgg ctcgtctcc	2700
35	ccatgcctgc ttcccgcccc ctgcccgtga cggcgtctc cgaggaccaa tgagcgcgt	2760
	gtatccaccc ctggggggg gccaagcgcc gaccaatcgc cgctggcgccggg	2820
40	tccaaacgct ccaatcgta gcggcggcgg ggcggcaga gggccgggaa tggcaggttc	2880
	aaccaacggg tggcacgtc gtcctcgca ggaggcgtgc cctcgccgg ggcgtcggt	2940
45	gtcccgccg ggcaggagggag ggggaggaggt gtaaacaaa tgccggccgc gtgtggcg	3000
	cggaaggggg aggccggcccg gggcccccgc gatgtaggcg cggggccgc aaggagcgc	3060
50	gggtggccgc acttgctgcc gccgccttgg atggctggg ccccccctgc cgctccgcct	3120
	cctccacacg cgccggccgc gccgcgagggg ggacgcgcgc cccggggccc ggcaccccg	3180

EP 1 036 844 A1

5 ggaacccccc ggcccgagc ctgcggctg cggccctcg gccgcggga gccccgtgga 3240
gcccccgccg ccgcggccgc ccgcggaccg gacgctgagg gcactcgaaa cggggcgcgc 3300
gctcggcag acgtttgcgg ggagggggc gcctgccggg cccggcgcac caccttgggg 3360
10 gtcgcggcc ggctcgaaaa ggcggccactg cggccctcg cgggcgcgg gcagcgacca 3420
gcccgtggcg gagctgtgg ccgcggccgg aggccctcccg gacgccccca gcccccgaa 3480
15 cgctcgcccg ggccggccgg agtcggccgc cccgggagg tccgctcggt cgtccgcgc 3540
ggagcgtttgcctggac aggccgtggg accggggcgt cgccggagac gcccccgac 3600
20 aagttggcgt ctccagggtgt ggggtcccg ggggttagcg acgtcgccga cccggctgt 3660
ggatggcg gcccggagaa gactgcgtc ggccgtgttc atacttgtcc gtggcctga 3720
gtccccggaa ggtatgaccta gcactgaaaa gccccggccg gcctc 3765
25 <210> 2
<211> 1006
<212> DNA
30 <213> Homo sapiens

<220>
<221> exon
<222> (1)..(628)
35 <220>
<221> intron
<222> (629)..(1006)
40 <400> 2
cccagggtcc ccgaggacga agttgaccct gaccggccg tctcccgat ttgaggcccg 60
45 ggtccccactg gaactcgctt ctgagccgcgc gtccggacc cccgggtgcgc gccgggtccgc 120
agaccctgca cgggcttgg actcgaccc gggactgacg tgtagaacaa tcgtttctgt 180
50 tggaaagaagg gttttccct tcctttggg gttttgttg cctttttttt ttctttttc 240
tttgtaaaaat ttggagaag ggaagtgcgg aaacaaggaa ggaccgctca cccgcggact 300

EP 1 036 844 A1

	cagggctggc ggccggactc caggaccctg ggtccagc atg gag gtg gtg gac ccg Met Glu Val Val Asp Pro	356
5	1 5	
	cag cag ctg ggc atg ttc acg gag ggc gag ctg atg tcg gtg ggt atg Gln Gln Leu Gly Met Phe Thr Glu Gly Glu Leu Met Ser Val Gly Met	404
10	10 15 20	
	gac acg ttc atc cac cgc atc gac tcc acc gag gtc atc tac cag ccg Asp Thr Phe Ile His Arg Ile Asp Ser Thr Glu Val Ile Tyr Gln Pro	452
15	25 30 35	
	cgc cgc aag cgg gcc aag ctc atc ggc aag tac ctg atg ggg gac ctg Arg Arg Lys Arg Ala Lys Leu Ile Gly Lys Tyr Leu Met Gly Asp Leu	500
20	40 45 50	
	ctg ggg gaa ggc tct tac ggc aag gtg aag gag gtg ctg gac tcg gag Leu Gly Glu Gly Ser Tyr Gly Lys Val Lys Glu Val Leu Asp Ser Glu	548
25	55 60 65 70	
	acg ctg tgc agg agg gcc gtc aag atc ctc aag aag aag ttg cga Thr Leu Cys Arg Arg Ala Val Lys Ile Leu Lys Lys Lys Leu Arg	596
30	75 80 85	
	agg atc ccc aac ggg gag gcc aac gtg aag aa gtaagtatggc ttgctgggt Arg Ile Pro Asn Gly Glu Ala Asn Val Lys Lys	649
35	90 95	
	cggggccggg cccggccagt cacgggtgtc atggtttgtt ctcccttct tctctccctcc	709
40	ctccctccct tacttccct taacaccctg agctggaccc gtctggcgcc tgtgtccctcc	769
	gtgcgcaggga gagcgtggtt gggggctgc gttacggact ttcaactcagg caaggccagt	829
45	tgtgcgcaggcg gggcgtgcgt ttgcattggc tcttgactc cagttaaaat gcccgttag	889
	cgaaacccctc ctgagaaggg aegggcccc aatccctaa gactagcccc ttggctcccc	949
50	cagctgtcca aggaggcagag gcgcggcagtg gaatcagcct gtgtttgttt gggcccc	1006
	<210> 3	
	<211> 5661	

EP 1 036 844 A1

5 <212> DNA
 <213> Homo sapiens

10 <220>
 <221> intron
 <222> (1)..(456)

15 <220>
 <221> exon
 <222> (457)..(540)

20 <220>
 <221> intron
 <222> (541)..(1363)

25 <220>
 <221> exon
 <222> (1364)..(1453)

30 <220>
 <221> intron
 <222> (1454)..(2412)

35 <220>
 <221> exon
 <222> (2413)..(2545)

40 <220>
 <221> intron
 <222> (2546)..(2620)

45 <220>
 <221> exon
 <222> (2621)..(2757)

50 <220>
 <221> intron
 <222> (2758)..(3252)

55 <220>
 <221> exon
 <222> (3253)..(3380)

EP 1 036 844 A1

5	<220>		
	<221> intron		
	<222> (3381)..(3988)		
10	<220>		
	<221> exon		
	<222> (3989)..(4046)		
15	<220>		
	<221> intron		
	<222> (4047)..(5024)		
20	<220>		
	<221> exon		
	<222> (5025)..(5212)		
25	<220>		
	<221> intron		
	<222> (5213)..(5661)		
30	<400> 3		
	ggtaaaaccc tgtctgtact aaaataaaaaaaa aaaatttagcc ggctgtggtg acacgtgcct	60	
	gtagtccccag ctactcggga ggctgaggca gggaaatcac ttgaacctgg gaggcagagg	120	
	ttgcagttagt ctgagatcgg gccaccgtgc tccagcctag ggacagagca agactctgtc	180	
35	tcaaaaaaaaaaaa aaaaaaaagtgt cctaactgtg tcctccaaag ccctcgccgg ccgtatgacag	240	
	actagagggc gctgtgtcc caccctcac cgcctgagc ctggacgegt ggccctgtca	300	
40	ggccctttc ccacagcact gtgaactcac agcttcttc taggaaaggg aggaggtacg	360	
	ccacttccac agggagatgg ggaggccgac tccagggatc caggccatca tcctgacgtt	420	
45	gggtcggctg atacacccct gtcctctctg tcccag g gaa att caa cta ctg agg	475	
	Glu Ile Gln Leu Leu Arg		
	100		
50	agg tta cggtt cac aaa aat gtc atc cag ctg gtg gat gtg tta tac aac	523	
	Arg Leu Arg His Lys Asn Val Ile Gln Leu Val Asp Val Leu Tyr Asn		
	105	110	115

EP 1 036 844 A1

	gaa gag aag cag aaa at atatccttcc ggtgttggga ccgcggggcc	571
5	Glu Glu Lys Gln Lys Met	
	120 125	
	tccgtggag gggctgggc cctgggtccg cctgcctcga ggcctgcctc tcttcccgtc	631
10	tccttgaagg agactggcac acgaggccg tggcctccc tggttccccg gaagtcagcc	691
	attgtggcaa tggctgeca gcttgctgaa agggccctg agccctggcc cctgtgttctt	751
15	gggcccgtgg ggtgtcaagt cccttttc tcagagtctc ctcccaggct aaccagggt	811
	gtagccacgg tctgcctgag acaggccacg cgggctgacc gttgtggcc attttgtcg	871
20	tggctggcg tgtcctcgta tcatctgtgg acaccccat gggtcttacg ggcacagcct	931
	ccctacgggg actttgttcc ctaaggccct gtgccagag caagagccag aagtggctt	991
25	gaggctgggg ctgtgttccc tgagccacgc ggtcagggc cctgggaccc tcctgcattgg	1051
	gccccagcct gcttgggggg gegtccagga ggcaccatcc cccgccccatg ggcagggtgg	1111
	gggacgtgag ccccgccagga acgctgcccc aagagtcagc cctgtctcc cttccccgt	1171
30	aggctccttc ctccctggac gctggggccc ctggccctt tcagaggggt ggctgaggc	1231
	agggtggcc ctggccccca ggagggcaaa ggtgggtgca gagggtccct ccagagcccc	1291
35	ttttctggcc cccgtgttcc ctggccctgt gagtggggcc gcccccttagt ctgtgttcc	1351
	tttagcccccc ac g tat atg gtg atg gag tac tgc gtg tgt ggc atg cag	1400
	Tyr Met Val Met Glu Tyr Cys Val Cys Gly Met Gln	
40	130 135	
	gaa atg ctg gac agc gtg ccg gag aag cgt ttc cca gtg tgc cag gcc	1448
45	Glu Met Leu Asp Ser Val Pro Glu Lys Arg Phe Pro Val Cys Gln Ala	
	140 145 150	
	cac gg gtgcgtgcgcg gggcaggggc caggggtggg cggggccgg gggccaggca	1504
	His Gly	
50	155	
	gggcaggctc cttccgtga ggccacactg cttgtcctga tattcattga catgaaggcc	1564

EP 1 036 844 A1

	caagttttt tgggttttg ttgttttgc ttgttttcg agatggagtc tcactctgc	1624
5	gcccgaggctg gagtgcaatg gtgcgatctc ggctcaactgc aagctccgcc tccgagggtc	1684
	acgccattct tctgcctcag cttcccaggt agctgggatt acaggcgccc gccaccacgc	1744
10	ccggctaatt ttttgtatTT ttagtagaga cggggtttca ccgtgttagc caggatggtc	1804
	tcaaactctt gacctcgtga tccgcctgcc tcagccccc aaagtgcgtgg gattacaggc	1864
15	atgagctacc acgccccggcc ttgtaaaaggc ccaagttttt aaaaacagtt ttgggtccc	1924
	ccatgtgtgg catccacagg caggcgtgct gccaacctcc cgccctccatc ttgcgtggc	1984
20	ctgctgcctg agggcagtgg cctgcctcca gcccacatcgct ggcagccgcc tgccctgacc	2044
	agatctcctg gatgcagggtc tggcctca gagtcaggc cccttgcgtgc tgcaggacca	2104
25	caggggcagg gaggggcctg ctgttccagc aagactttgg ggtgcagccg gcctgtggcc	2164
	cacagaaaaa tgagacctgt ggacatccgg gcccctgcca gacgtggctc ggccggacga	2224
30	gggtggccac tgcaggcgca ggtgtggctc cctgcgtggac ctgccttgc ctctgtcctg	2284
	tgtgccttggc ctctgtgac ttccctgtggt gtttgggagg ctcccaggca	2344
35	gctgcaaagg ggaccctgt gaggggcagg gaggcctcgg ccccaggacg ggtgtgtgtc	2404
	gccccgcag g tac ttc tgt cag ctg att gac ggc ctg gag tac ctg cat	2452
	Tyr Phe Cys Gln Leu Ile Asp Gly Leu Glu Tyr Leu His	
40	160	165
	agc cag ggc att gtg cac aag gac atc aag ccg ggg aac ctg ctg ctc	2500
	Ser Gln Gly Ile Val His Lys Asp Ile Lys Pro Gly Asn Leu Leu Leu	
45	170	175
	180	
	acc acc ggt ggc acc ctc aaa atc tcc gac ctg ggc gtg gcc gag	2545
	Thr Thr Gly Gly Thr Leu Lys Ile Ser Asp Leu Gly Val Ala Glu	
50	185	190
	195	
	gtaggcacgt gctagggggg gcccctgggc gccccctccc gggcactccc tgaggcgtc	2605

EP 1 036 844 A1

	acggcaccgc cacag gca ctg cac ccg ttc gcg gcg gac gac acc tgc cgg Ala Leu His Pro Phe Ala Ala Asp Asp Thr Cys Arg 200 205 210	2656
5		
	acc agc cag ggc tcc ccg gct ttc cag ccg ccc gag att gcc aac ggc Thr Ser Gln Gly Ser Pro Ala Phe Gln Pro Pro Glu Ile Ala Asn Gly 215 220 225	2704
10		
	ctg gac acc ttc tcc ggc ttc aag gtg gac atc tgg tcg gct ggg gtc Leu Asp Thr Phe Ser Gly Phe Lys Val Asp Ile Trp Ser Ala Gly Val 230 235 240	2752
15		
	acc ct gtaagtgcggccccccgg gcactcacca cacgcacact ccgaggggcc Thr Leu 245	2808
20		
	tctgcgttt gggcagctgc cggcctgtgg gcgcaggcg tggccaccgg cccagaccct	2868
25		
	ctctggccac agccgctagg gggtgcttac tttatggaaa tgtaactcat acggcagatg	2928
	gtggttcacc cgtgtgaagt gcagcctggc ccgtcaggga tcttcacaga gtggcacggc	2988
	cgaccctctt cccagagccc cacaggaaag ctgggggggt gacagcagct ccaggccct	3048
30		
	tccccgggtg ggtccagagg acactccctt cctacccgt agectccact agtggaaagg	3108
	gtgtaaagaca gaggtgttct tgagtccaca gggccttgg tccagcagcc acgggacgcc	3168
35		
	tctgtccctg ggtagagct gggcttcta gggcgtcaac cacttgact gaccacgct	3228
	tttttccttc ccctcgaaat gaag c tac aac atc acc acg ggt ctg tac ccc Tyr Asn Ile Thr Thr Gly Leu Tyr Pro 250	3280
40		
	ttc gaa ggg gac aac atc tac aag ttg ttt gag aac atc ggg aag ggg Phe Glu Gly Asp Asn Ile Tyr Lys Leu Phe Glu Asn Ile Gly Lys Gly 255 260 265 270	3328
45		
	agc tac gcc atc ccg ggc gac tgt ggc ccc ccg ctc tct gac ctg ctg Ser Tyr Ala Ile Pro Gly Asp Cys Gly Pro Pro Leu Ser Asp Leu Leu 275 280 285	3376
50		
	aaa g gtgggagcctca tccctctgcc cgccagccca gggaggcggtt gctttgtgc	3432

Lys

5	agaaatgtag gttgggggt gtcaggtggg gggctattgg ccccgagacc ccagcaggca	3492
10	ttgagaggac tgagtggaga ggccgaccc tc cccgcaggc ctggtttgc aggtccctca	3552
15	gtccaccct gcttctggc cctgttacc accccaga gggcagtgt	3612
20	gccctgcgc tccccagcc ccacctcgg gggctccctg gcttgcaggg tctgtcagg	3672
25	ttgtctgtc acatcccta cgcattggcag cagggtggcac tggcgtccg tccatctgc	3732
30	cagtggcctt gggagaacgg aaccgcctg gccgtccagc ccagccctgt ctccctgcca gcccgcaca ggctgtcccc ggcatgtccc aggagtggag tggctctgt cagggagacc gcctgtgcgc ggggtcccccc ttaggagctt ccaggtatca cccaggcct gacaacagag gctggcagg cggggacggt tggtgggtc tcaggctgt gcccagctga caggctcc gccgcttct cctcag gg atg ctt gag tac gaa ccg gcc aag agg ttc tcc Gly Met Leu Glu Tyr Glu Pro Ala Lys Arg Phe Ser 290 295	3792 3852 3912 3972 4023
35	atc cgg cag atc cgg cag cac ag gtgagccccc ctggggcag tggggccag Ile Arg Gln Ile Arg Gln His Ser 300 305	4077
40	gctgcaggga gcgcgcattt gtggcactt gttgagcgg gcttagagc agggcgttgt	4137
45	gggggtgcgc ggcgtggctg gggccagacc cctgcagcg cccgcatttgc tggggcccg agtgggtct ctggcacttgc ttctgttacc gcccagaccc aggcgccttg tccgaactgg ggtctgatgtt aggcacatgcg tccgtccctg ccctaggcat ggagatgcgc caggaaggc acagctggtc ccaaactg gcgagaccc ctcttttcc ctctctcttgc gggctcccg cagcagggtt tggctggat ccagccagg gcccagctt ccatgacagg gaagacagag cagcggacgg ggtcagcagg cccacagtg ccgcctccctt cacttcgtgg gctctgtcc	4197 4257 4317 4377 4437 4497

EP 1 036 844 A1

	tctgcaccag cccctggagg cccttgcgcc gtctgtgga gcccctcga gccccgaggc	4557
5	cacccactga gaccggctct gggagtggga gtgtccggac ccctgaggcg ctggtgtcga	4617
	tttgccitg ggggtctctg cacagctcgg gtcatctggg cgccctggcgg ggactgggc	4677
10	tgc(cccccga tagcctcctg ggctggatg tgctcaggc cccccagacc cccttctggc	4737
	ctttgtggc tttgcagcca gcatccatct ggtgggtgct ggcttctgag tgccacactgg	4797
15	gacacaggcc tcagggtgga gggacatct gtcaggcttg gagtcaggc agcctgcctg	4857
	ctcctagagg acatggctga gcttctgtgg tcacagccac cccttgcacg gcctggtccc	4917
20	agctcctgag tgtgtggcag gtacctggg cccagaggag ctgggtcggaa aaactggacc	4977
	gccctggtgc cagcctgaca ggcgccactg cttctggcgt tttgcag c tgg ttc cgg	5034
	Trp Phe Arg	
	310	
25	aag aaa cat cct ccg gct gaa gca cca gtg ccc atc cca ccg agc cca Lys Lys His Pro Pro Ala Glu Ala Pro Val Pro Ile Pro Pro Ser Pro	5082
	315 320 325	
30	gac acc aag gac egg tgg cgc agc atg act gtg gtg ccg tac ttg gag Asp Thr Lys Asp Arg Trp Arg Ser Met Thr Val Val Pro Tyr Leu Glu	5130
	330 335 340	
35	gac ctg cac ggc gcg gac gag gac gac ctc ttc gac atc gag gat Asp Leu His Gly Ala Asp Glu Asp Glu Asp Leu Phe Asp Ile Glu Asp	5178
	345 350 355	
40	gac atc atc tac act cag gac ttc acg gtg ccc g gtgagtctggcg Asp Ile Ile Tyr Thr Gln Asp Phe Thr Val Pro	5224
	360 365	
45	ggggccccctg cccggctctg ctgactcggc caggatgtcc cacgggagca gggtgcctgc	5284
	ctgtctgcaa caaggacagc ttctgcctc tggtgccaa tcccacgtcc ccaaagcctc	5344
50	cagccccact gcaggctgcc tccgcctgc gggccgtgg gacatggctg aaagggtgtgg	5404
	ggtcagcggg ggcaccagcc caggcctgtc tggccaggag gtttcctcag gcgtctctcc	5464

EP 1 036 844 A1

5	gggtgctgcc cagccaggca ccacccaccc gccttggcct gagtcccagc aggagcaggc	5524
	gggggagccc cagggtcggg ggagggttagg tgagagtcag ggtgcagggt ggcccctcag	5584
	acagctggca ttagagaggg tccagtgcc ctccctcccg tgcgtccctga ggccctgccc	5644
10	ctggccctga tgccggc	
	5661	
15	<210> 4	
	<211> 2095	
	<212> DNA	
	<213> Homo sapiens	
20	<220>	
	<221> intron	
	<222> (1)..(454)	
25	<220>	
	<221> exon	
	<222> (455)..(2095)	
30	<400> 4	
	tttcgcgtgc ctggcctgag cctggccga gcctggccct cctgtgtcct cacagatgag	60
35	catgtggcgg ctccctggcc tctagaacca accatggcc agggtgcccc aggggagcac	120
	gggagggtcc tgccttgtca gcttgcctcc tactcgttag gttcctgcag tcagtacctg	180
40	ggtgtgggtcc cacctgcggc catggcaggt gcaacagacg tggtgaggg gacactcctg	240
	cccagccat ctgcgggagg ctcagccccc gggggtcct cccagagctg ctggggggca	300
45	gcatttcagg ctggatacac ctggcctga cccggggcgc ggcattggcct gggcagcagc	360
	tgttaagtgcg tccccgtgtt gggggccagc caggtccctg tggctctggg gttgcgc	420
50	tcagctcagg ccacacttgc cgtctccctc ccag ga cag gtc cca gaa gag gag	474
	Gly Gln Val Pro Glu Glu Glu	
	370 375	

EP 1 036 844 A1

	gcc agt cac aat gga cag cgc cgg ggc ctc ccc aag gcc gtg tgt atg Ala Ser His Asn Gly Gln Arg Arg Gly Leu Pro Lys Ala Val Cys Met	522
5	380 385 390	
	aac ggc aca gag gcg gcg cag ctg agc acc aaa tcc agg ggc gag ggc Asn Gly Thr Glu Ala Ala Gln Leu Ser Thr Lys Ser Arg Ala Glu Gly	570
10	395 400 405	
	cgg gcc ccc aac cct gcc cgc aag gcc tgc tcc gcc agc agc aag atc Arg Ala Pro Asn Pro Ala Arg Lys Ala Cys Ser Ala Ser Ser Lys Ile	618
15	410 415 420	
	cgc cgg ctg tcg gcc tgc aag cag cag tgaggctggc cgcctgcagg Arg Arg Leu Ser Ala Cys Lys Gln Gln	665
20	425 430	
	tggggcgccgg cggggcccggtggggcatgtggggacaac gcctggatgc cacagccaggc	725
25	cgtgagcata gccccgccta gtcagtcatgtgtaccgtca cgtggctgcgcgtgggtgc	785
	atgtggcctt tgggtggctt ggccacgttag cgatccccgt ggagggtgcc gtctcgggc	845
30	ctgggtgtctg gccagcgtgc tggcatgga ggctacgttgccggggct ctggggggc	905
	gtgccgtcct cacagccacc tctcagactggtgccattcc gaggaccctgcctggc	965
35	ggcgccccct cccatggcc gcccgccttc cagggaaaggcttacgtggctcagccag	1025
	aggctttga gcaccagtgg gtgggggtgtggggaggg gcccggccctccatggctct	1085
40	gcccgggtgc cgcaggctctgagccagctgccaagttatggctggtgcattcc	1145
	acgctgcctgtctccctgtgtgcctgccttccttcctccctccctccctccctccctcc	1205
45	gtgggagacggatcccaga ggtgtcagagacccttaagtcacctggcgagatgcgggg	1265
	tggatggggcccgaggctgaagccctgccttgcacagcccttcctccctccctccctcc	1325
50	ggccaccgcctc ttagttacatgtctcccccaaatgggtgcacageccatccaccaggc	1385
	gtcagagccgcaggccccactgaaaaag gcccacacaatgtacccggaggatgactcaa	1445
	gggtggcctt ccctggcctccctgtgcctccctggaggatccgttagcccatgactgtaa	1505

EP 1 036 844 A1

cctcagcttc tccatcctcc caggggcccg cgggaggcgg agaaccggtg cccaggctga 1565
5 cctcttccgt cttccttcca ccctgcagcc cgtgtccagg agccccgcca ggtccccgcg 1625
ccagggccctc agtcttcctg ccgggttccgc ccgcctccc ggagaggtgg ccgcctatgt 1685
10 tctgtgccga ccacgccccca ggacctccgg agcgccctgc agggccggc agggggacag 1745
cagggaccgg gcgcagccct ccccccctcgg ccgcggcgtca gtgcacgcgg cttgttgcact 1805
15 tcgcagcccc gggcggagcc ttcccgccgg ggcgtggag gagggaggcgc gcctccatgc 1865
actttatgtg gagactactg gccccgccc tggcctcgtg ctccgcaggg cgcccgagcgc 1925
20 cgtccggcgg ccccgccgca gaccagctgg cgggtgtgga gaccaggctc ctgaccccg 1985
catgcattgca gcgcacactg gaagccgcgc ggccgccttg gttttttttt tggttggttc 2045
25 cattttttt tttttttttt ttttttaaga aaaaataaaaaa ggtggattt 2095

25 <210> 5
30 <211> 1302
<212> DNA
<213> Homo sapiens

35 <220>
<221> CDS
<222> (1)..(1302)

40 <400> 5
atg gag gtg gtg gac ccg cag cag ctg ggc atg ttc acg gag ggc gag 48
Met Glu Val Val Asp Pro Gln Gln Leu Gly Met Phe Thr Glu Gly Glu
1 5 10 15

45 ctg atg tcg gtg ggt atg gac acg ttc atc cac cgc atc gac tcc acc 96
Leu Met Ser Val Gly Met Asp Thr Phe Ile His Arg Ile Asp Ser Thr
20 25 30

50 gag gtc atc tac cag ccg cgc cgc aag cgg gcc aag ctc atc ggc aag 144
Glu Val Ile Tyr Gln Pro Arg Arg Lys Arg Ala Lys Leu Ile Gly Lys
35 40 45

EP 1 036 844 A1

	tac ctg atg ggg gac ctg ctg ggg gaa ggc tct tac ggc aag gtg aag Tyr Leu Met Gly Asp Leu Leu Gly Glu Gly Ser Tyr Gly Lys Val Lys	192
5	50 55 60	
	gag gtg ctg gac tcg gag acg ctg tgc agg agg gcc gtc aag atc ctc Glu Val Leu Asp Ser Glu Thr Leu Cys Arg Arg Ala Val Lys Ile Leu	240
10	65 70 75 80	
	aag aag aag ttg cga agg atc ccc aac ggg gag gcc aac gtg aag Lys Lys Lys Leu Arg Arg Ile Pro Asn Gly Glu Ala Asn Val Lys	288
15	85 90 95	
	aag gaa att caa cta ctg agg agg tta cgg cac aaa aat gtc atc cag Lys Glu Ile Gln Leu Leu Arg Arg Leu Arg His Lys Asn Val Ile Gln	336
20	100 105 110	
	ctg gtg gat gtg tta tac aac gaa gag aag cag aaa atg tat atg gtg Leu Val Asp Val Leu Tyr Asn Glu Glu Lys Gln Lys Met Tyr Met Val	384
25	115 120 125	
	atg gag tac tgc gtg tgt ggc atg cag gaa atg ctg gac agc gtg ccg Met Glu Tyr Cys Val Cys Gly Met Gln Glu Met Leu Asp Ser Val Pro	432
30	130 135 140	
	gag aag cgt ttc cca gtg tgc cag gcc cac ggg tac ttc tgt cag ctg Glu Lys Arg Phe Pro Val Cys Gln Ala His Gly Tyr Phe Cys Gln Leu	480
35	145 150 155 160	
	att gac ggc ctg gag tac ctg cat agc cag ggc att gtg cac aag gac Ile Asp Gly Leu Glu Tyr Leu His Ser Gln Gly Ile Val His Lys Asp	528
40	165 170 175	
	atc aag ccg ggg aac ctg ctg ctc acc acc ggt ggc acc ctc aaa atc Ile Lys Pro Gly Asn Leu Leu Leu Thr Thr Gly Gly Thr Leu Lys Ile	576
45	180 185 190	
	tcc gac ctg ggc gtg gcc gag gca ctg cac ccg ttc gcg gcg gac gac Ser Asp Leu Gly Val Ala Glu Ala Leu His Pro Phe Ala Ala Asp Asp	624
50	195 200 205	
	acc tgc cgg acc agc cag ggc tcc ccg gct ttc cag ccg ccc gag att Thr Cys Arg Thr Ser Gln Gly Ser Pro Ala Phe Gln Pro Pro Glu Ile	672

EP 1 036 844 A1

	210	215	220	
5	gcc aac ggc ctg gac acc ttc tcc ggc ttc aag gtg gac atc tgg tcg Ala Asn Gly Leu Asp Thr Phe Ser Gly Phe Lys Val Asp Ile Trp Ser			720
	225	230	235	240
10	gct ggg gtc acc ctc tac aac atc acc acg ggt ctg tac ccc ttc gaa Ala Gly Val Thr Leu Tyr Asn Ile Thr Thr Gly Leu Tyr Pro Phe Glu			768
	245	250	255	
15	ggg gac aac atc tac aag ttg ttt gag aac atc ggg aag ggg agc tac Gly Asp Asn Ile Tyr Lys Leu Phe Glu Asn Ile Gly Lys Gly Ser Tyr			816
	260	265	270	
20	gcc atc ccg ggc gac tgt ggc ccc ccg ctc tct gac ctg ctg aaa ggg Ala Ile Pro Gly Asp Cys Gly Pro Pro Leu Ser Asp Leu Leu Lys Gly			864
	275	280	285	
25	atg ctt gag tac gaa ccg gcc aag agg ttc tcc atc cgg cag atc cgg Met Leu Glu Tyr Glu Pro Ala Lys Arg Phe Ser Ile Arg Gln Ile Arg			912
	290	295	300	
30	cag cac agc tgg ttc cgg aag aaa cat cct ccg gct gaa gca cca gtg Gln His Ser Trp Phe Arg Lys Lys His Pro Pro Ala Glu Ala Pro Val			960
	305	310	315	320
35	ccc atc cca ccg agc cca gac acc aag gac cgg tgg cgc agc atg act Pro Ile Pro Pro Ser Pro Asp Thr Lys Asp Arg Trp Arg Ser Met Thr			1008
	325	330	335	
40	gtg gtg ccg tac ttg gag gac ctg cac ggc gcg gac gag gac gag gac Val Val Pro Tyr Leu Glu Asp Leu His Gly Ala Asp Glu Asp Glu Asp			1056
	340	345	350	
45	ctc ttc gac atc gag gat gac atc atc tac act cag gac ttc acg gtg Leu Phe Asp Ile Glu Asp Asp Ile Ile Tyr Thr Gln Asp Phe Thr Val			1104
	355	360	365	
50	ccc gga cag gtc cca gaa gag gag gcc agt cac aat gga cag cgc egg Pro Gly Gln Val Pro Glu Glu Ala Ser His Asn Gly Gln Arg Arg			1152
	370	375	380	
55	ggc ctc ccc aag gcc gtg tgt atg aac ggc aca gag gcg gcg cag ctg			1200

EP 1 036 844 A1

	Gly Leu Pro Lys Ala Val Cys Met Asn Gly Thr Glu Ala Ala Gln Leu			
385	390	395	400	
5	agc acc aaa tcc agg gcg gag ggc cgg gcc ccc aac cct gcc cgc aag Ser Thr Lys Ser Arg Ala Glu Gly Arg Ala Pro Asn Pro Ala Arg Lys		1248	
	405	410	415	
10	gcc tgc tcc gcc agc agc aag atc cgc cgg ctg tcg gcc tgc aag cag Ala Cys Ser Ala Ser Ser Lys Ile Arg Arg Leu Ser Ala Cys Lys Gln		1296	
	420	425	430	
15	cag tga			
	1302			
	Gln			
20	<210> 6			
	<211> 433			
	<212> PRT			
	<213> Homo sapiens			
25	<400> 6			
	Met Glu Val Val Asp Pro Gln Gln Leu Gly Met Phe Thr Glu Gly Glu			
	1	5	10	15
30	Leu Met Ser Val Gly Met Asp Thr Phe Ile His Arg Ile Asp Ser Thr			
	20	25	30	
35	Glu Val Ile Tyr Gln Pro Arg Arg Lys Arg Ala Lys Leu Ile Gly Lys			
	35	40	45	
40	Tyr Leu Met Gly Asp Leu Leu Gly Glu Gly Ser Tyr Gly Lys Val Lys			
	50	55	60	
45	Glu Val Leu Asp Ser Glu Thr Leu Cys Arg Arg Ala Val Lys Ile Leu			
	65	70	75	80
50	Lys Lys Lys Lys Leu Arg Arg Ile Pro Asn Gly Glu Ala Asn Val Lys			
	85	90	95	
55	Lys Glu Ile Gln Leu Leu Arg Arg Leu Arg His Lys Asn Val Ile Gln			
	100	105	110	
	Leu Val Asp Val Leu Tyr Asn Glu Glu Lys Gln Lys Met Tyr Met Val			

EP 1 036 844 A1

	115	120	125
5	Met Glu Tyr Cys Val Cys Gly Met Gln Glu Met Leu Asp Ser Val Pro		
	130	135	140
10	Glu Lys Arg Phe Pro Val Cys Gln Ala His Gly Tyr Phe Cys Gln Leu		
	145	150	155
	Ile Asp Gly Leu Glu Tyr Leu His Ser Gln Gly Ile Val His Lys Asp		
	165	170	175
15	Ile Lys Pro Gly Asn Leu Leu Leu Thr Thr Gly Gly Thr Leu Lys Ile		
	180	185	190
20	Ser Asp Leu Gly Val Ala Glu Ala Leu His Pro Phe Ala Ala Asp Asp		
	195	200	205
	Thr Cys Arg Thr Ser Gln Gly Ser Pro Ala Phe Gln Pro Pro Glu Ile		
	210	215	220
25	Ala Asn Gly Leu Asp Thr Phe Ser Gly Phe Lys Val Asp Ile Trp Ser		
	225	230	235
	Ala Gly Val Thr Leu Tyr Asn Ile Thr Thr Gly Leu Tyr Pro Phe Glu		
30	245	250	255
	Gly Asp Asn Ile Tyr Lys Leu Phe Glu Asn Ile Gly Lys Gly Ser Tyr		
35	260	265	270
	Ala Ile Pro Gly Asp Cys Gly Pro Pro Leu Ser Asp Leu Leu Lys Gly		
	275	280	285
40	Met Leu Glu Tyr Glu Pro Ala Lys Arg Phe Ser Ile Arg Gln Ile Arg		
	290	295	300
	Gln His Ser Trp Phe Arg Lys Lys His Pro Pro Ala Glu Ala Pro Val		
45	305	310	315
	Pro Ile Pro Pro Ser Pro Asp Thr Lys Asp Arg Trp Arg Ser Met Thr		
	325	330	335
50	Val Val Pro Tyr Leu Glu Asp Leu His Gly Ala Asp Glu Asp Glu Asp		
	340	345	350

Leu Phe Asp Ile Glu Asp Asp Ile Ile Tyr Thr Gln Asp Phe Thr Val
355 360 365

5 Pro Gly Gln Val Pro Glu Glu Ala Ser His Asn Gly Gln Arg Arg
370 375 380

10 Gly Leu Pro Lys Ala Val Cys Met Asn Gly Thr Glu Ala Ala Gln Leu
385 390 395 400

15 Ser Thr Lys Ser Arg Ala Glu Gly Arg Ala Pro Asn Pro Ala Arg Lys
405 410 415

20 Ala Cys Ser Ala Ser Ser Lys Ile Arg Arg Leu Ser Ala Cys Lys Gln
420 425 430

Gln

25 <210> 7

<211> 21

<212> DNA

<213> Artificial Sequence

30 <220>

<223> Description of Artificial Sequence: "DJ698", an artificially synthesized primer sequence

35 <400> 7

ggtccccc gag gacgaagttg a

21

40 <210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

45 <220>

<223> Description of Artificial Sequence: "DJ673", an artificially synthesized primer sequence

50 <400> 8

accatcagca ccgtgactgg

20

5 <210> 9

<211> 18

<212> DNA

<213> Artificial Sequence

10 <220>

<223> Description of Artificial Sequence: "DJ703", an artificially synthesized primer sequence

15 <400> 9

tcggccggccg atgacaga

18

20 <210> 10

<211> 22

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence: "DJ674", an artificially synthesized primer sequence

30 <400> 10

aaggagacgg gaagaggaggc ag

22

35 <210> 11

<211> 19

<212> DNA

<213> Artificial Sequence

40 <220>

<223> Description of Artificial Sequence: "DJ690", an artificially synthesized primer sequence

45 <400> 11

gaggaggggc aaggtgggt

19

50 <210> 12

<211> 21

<212> DNA

<213> Artificial Sequence

55 <220>

<223> Description of Artificial Sequence: "DJ680", an artificially

synthesized primer sequence

5 <400> 12
gtgtggcctc acggaaagga g 21

10 <210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

15 <220>
<223> Description of Artificial Sequence: "DJ692", an artificially synthesized primer sequence

20 <400> 13
agctgggcct gtggtgtttg 20

25 <210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Description of Artificial Sequence: "DJ694", an artificially synthesized primer sequence

35 <400> 14
cagaggcccc tcggagtgtg 20

40 <210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: "DJ695", an artificially synthesized primer sequence

50 <400> 15
gcctctgtcc ctggggtaga 20

<210> 16
<211> 22

5 <212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: "DJ693", an artificially synthesized primer sequence

15 <400> 16
tcagtcctct caatgcctgc tg 22

20 <210> 17
<211> 19
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence: "DJ696", an artificially synthesized primer sequence

30 <400> 17
gcggggtccc ccttaggag 19

35 <210> 18
<211> 19
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence: "DJ697", an artificially synthesized primer sequence

45 <400> 18
ctagcgcccg ctcaaccag 19

50 <210> 19
<211> 22
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Description of Artificial Sequence: "DJ675", an artificially synthesized primer sequence

<400> 19
ggagctgggt cgaaaaactg ga

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: "DJ702", an artificially synthesized primer sequence

<400> 20
tgctcccgta gacatcctg 20

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: "DJ676", an artificially synthesized primer sequence

<400> 21
gttaagtgcgt ccccggttgt 20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: "DJ677", an artificially synthesized primer sequence

<400> 22
gtggcatcca ggcgttgtcc 20

<210> 23
<211> 22
<212> DNA
<213> Artificial Sequence

5 <220>
10 <223> Description of Artificial Sequence: "DJ705", an artificially
15 synthesized primer sequence 22

<400> 23
ggaaattcgg aacacaagga ag

10 <210> 24
<211> 19
<212> DNA
15 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: "DJ649", an artificially
20 synthesized primer sequence

<400> 24
atggaggtgg tggacccgc 19

25 <210> 25
<211> 24
<212> DNA
30 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: "DJ659", an artificially
35 synthesized primer sequence

<400> 25
gttacggcac aaaaatgtca tcca 24

40 <210> 26
<211> 21
<212> DNA
45 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: "DJ666", an artificially
50 synthesized primer sequence

<400> 26
ggtagatggag tactgcgtgt g 21

5 <210> 27

<211> 21

<212> DNA

<213> Artificial Sequence

10 <220>

<233> Description of Artificial Sequence: "DJ684", an artificially synthesized primer sequence

15 <400> 27

acatcgggaa ggggagctac g

21

20 <210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

25 <220>

<233> Description of Artificial Sequence: "DJ660", an artificially synthesized primer sequence

30 <400> 28

ccgggcaccg tgaagtccctg

20

35 <210> 29

<211> 19

<212> DNA

<213> Artificial Sequence

40 <220>

<233> Description of Artificial Sequence: "DJ650", an artificially synthesized primer sequence

45 <400> 29

tcaactgtgc ttgcaggcc

19

50 <210> 30

<211> 17

<212> DNA

<213> Artificial Sequence

55 <220>

EP 1 036 844 A1

<223> Description of Artificial Sequence: "DJ717", an artificially synthesized primer sequence

5 <400> 30
gcaggcgccc agcctca 17

10 <210> 31
 <211> 19
 <212> PRT
 <213> *Homo sapiens*

15 <400> 31
Cys Leu Ser Thr Lys Ser Arg Ala Glu Gly Arg Ala Pro Asn Pro Ala
1 5 10 15

20 Arg Lys Ala

25 <210> 32
<211> 20
<212> PRT
<213> *Homo sapiens*

30 <400> 32
Cys Ile Arg Gln Ile Arg Gln His Ser Trp Phe Arg Lys Lys His Pro
1 5 10 15

Pro Ala Glu Ala
20

<210> 33
<211> 20
<212> PRT
<213> *Homo sapiens*

45 <400> 33
 Cys Phe Glu Gly Asp Asn Ile Tyr Lys Leu Phe Glu Asn Ile Gly Lys
 1 5 10 15

Gly Ser Tyr Ala
20

<210> 34

<211> 20

<212> PRT

<213> Homo sapiens

5 <400> 34

Cys His Arg Ile Asp Ser Thr Glu Val Ile Tyr Gln Pro Arg Arg Lys

10 1

5

10

15

Arg Ala Lys Leu
20

15 <210> 35

<211> 22

<212> DNA

<213> Artificial Sequence

20 <220>

<223> Description of Artificial Sequence: "DJ180", an artificially synthesized primer sequence

25 <400> 35

cgactcacta tagggagacc ca

22

30 <210> 36

<211> 22

<212> DNA

<213> Artificial Sequence

35 <220>

<223> Description of Artificial Sequence: "DJ181", an artificially synthesized primer sequence

40 <400> 36

cctcgagaat taccctcaact aa

22

45 <210> 37

<211> 17

<212> DNA

<213> Artificial Sequence

50 <220>

<223> Description of Artificial Sequence: an artificially synthesized primer sequence

<213> Artificial Sequence

5 <220>

<223> Description of Artificial Sequence: an artificially synthesized
c-Myc partial sequence

10 <400> 41

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
1 5 10

15 <210> 42

<211> 63

<212> DNA

<213> Artificial Sequence

20 <220>

<223> Description of Artificial Sequence: "LK E4", an artificially
synthesized primer sequence

25 <400> 42

gatggccct tacagggagg catagtcagg cacatcatat gggtactgct gcttgcaggc 60
cga 63

30 <210> 43

<211> 48

<212> DNA

<213> Artificial Sequence

35 <220>

<223> Description of Artificial Sequence: "LK E5", an artificially
synthesized primer sequence

40 <400> 43

gatgaattct tagtgatgg t gatggtgatg ctgctgctt cagggcga 48

45 <210> 44

<211> 11

<212> PRT

<213> Artificial Sequence

50 <220>

<223> Description of Artificial Sequence: an artificially synthesized HA
partial sequence

<400> 44

Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu
1 5 10

<210> 45

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: "LK D176N", an artificially synthesized primer sequence

<400> 45

attgtgcaca agaacatcaa gccgggg

27

<210> 46

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: "LK W308C", an artificially synthesized primer sequence

<400> 46

cggcagcaca gctgcttccg gaagaaaa

27

<210> 47

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: "LK L67P", an artificially synthesized primer sequence

<400> 47

gtgaaggagg tgccggactc ggagacg

27

<210> 48

<211> 27

<212> DNA

<213> Artificial Sequence

5

<220>

<223> Description of Artificial Sequence: "LK K1", an artificially synthesized primer sequence

10

<400> 48

aggagggccg tcatcatcct caagaag

27

15

Claims

20

1. A primer DNA used for diagnosing a disease caused by mutation in the LKB1 gene, the primer DNA comprising a nucleotide sequence containing at least a portion of any one of the nucleotide sequences shown in SEQ ID NOs: 1 to 4.
2. The primer DNA according to claim 1, wherein the primer DNA has a nucleotide sequence corresponding to any one of the nucleotide sequences shown in SEQ ID NOs: 7 to 30.
3. The primer DNA according to claim 1 or 2, wherein the disease caused by mutation in the LKB1 gene is Peutz-Jeghers syndrome.

30

4. A probe DNA used for diagnosing a disease caused by mutation in the LKB1 gene, the probe DNA comprising a nucleotide sequence containing at least a portion of any one of the nucleotide sequences shown in SEQ ID NOs: 1 to 4.
5. The probe DNA according to claim 4, wherein the disease caused by mutation in the LKB1 gene is Peutz-Jeghers syndrome.
6. A therapeutic preparation for a disease caused by mutation in the LKB1 gene, the preparation comprising the LKB1 gene as an active ingredient.

40

7. A therapeutic preparation for a disease caused by mutation in the LKB1 gene, the preparation comprising the LKB1 protein an active ingredient.
8. A therapeutic preparation for a disease caused by mutation in the LKB1 gene, the preparation comprising a compound that enhances the activity of LKB1 protein as an active ingredient.
9. The therapeutic preparation according to claims 6 to 8, wherein the disease caused by mutation in the LKB1 gene is Peutz-Jeghers syndrome.

50

10. A reagent for diagnosing a disease caused by mutation in the LKB1 gene, the reagent comprising an antibody that binds to the LKB1 protein as an active ingredient.
11. The reagent according to claim 10, wherein the disease caused by mutation in the LKB1 gene is Peutz-Jeghers syndrome.
12. A method of diagnosing a disease caused by mutation in the LKB1 gene, the method comprising detecting mutation in the LKB1 gene.

55

EP 1 036 844 A1

13. A method of diagnosing a disease caused by mutation in the LKB1 gene, the method comprising the steps of:

- (a) preparing a DNA sample from a patient;
- (b) amplifying the DNA using the primer DNA according to (1) ;
- 5 (c) cleaving the amplified DNA;
- (d) fractionating the DNA fragments according to their size;
- (e) hybridizing the probe DNA according to (4) with the fractionated DNA fragments; and
- (f) comparing the size of the DNA fragment thus detected to that from a control of a healthy subject.

10 14. A method of diagnosing a disease caused by mutation in the LKB1 gene, the method comprising the steps of:

- (a) preparing a RNA sample from a patient;
- (b) fractionating the RNA sample depending on its size;
- 15 (c) hybridizing the probe DNA according to (4) with the RNA thus fractionated;
- (d) comparing the size of the RNA thus detected to that from a control of a healthy subject.

15. A method of diagnosing a disease caused by mutation in the LKB1 gene, the method comprising the steps of:

- (a) preparing a DNA sample from a patient;
- 20 (b) amplifying the DNA using the primer DNA according to (1) ;
- (c) separating the amplified DNA into single stranded DNA;
- (d) fractionating the separated single stranded DNA on the non-denatured gel;
- (e) comparing the mobility of the single stranded DNA separated on the non-denatured gel to that of a control of a healthy subject.

25 16. A method of diagnosing a disease caused by mutation in the LKB1 gene, the method comprising the steps of:

- (a) preparing a DNA sample from a patient;
- (b) amplifying the DNA using the primer DNA according to (1);
- 30 (c) fractionating the amplified DNA on the DNA denatured gradient gel;
- (d) comparing the mobility of the fractionated DNA on the gel to that of a control of a healthy subject.

17. The method according to any one of claims 12 to 16, wherein the disease caused by mutation in the LKB1 gene is Peutz-Jeghers syndrome.

35

40

45

50

55

Figure 1




Figure 2





Figure 3



EP 1 036 844 A1

Figure 4



EP 1 036 844 A1

Figure 5




Figure 6




Figure 7




Figure 8





Figure 9




EP 1 036 844 A1

Figure 10



EP 1 036 844 A1

Figure 11



EP 1 036 844 A1

Figure 12



INTERNATIONAL SEARCH REPORT		International application No. PCT/JP98/05357
A. CLASSIFICATION OF SUBJECT MATTER Int.Cl' C12N15/12, 15/54, 15/63, C12Q1/68, C07K16/40, A61K48/00, 38/43, 33/32 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl' C12N15/09-15/90, C12Q1/68, C07K16/40, A61K48/00, 38/43, 33/32		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE (STN), WPI/L (DIALOG)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP, 8-308586, A (Chugai Pharmaceutical Co., Ltd.), 26 November, 1996 (26. 11. 96) & WO, 96/28554, A1 & AU, 9649552, A & EP, 816501, A1 & US, 5827726, A	1-2, 4, 6-8, 10, 12-16
A		3, 5, 9, 11, 17
P, X	Jenne, E.T., et al., "Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase", Nature Genetics, Vol. 18, No. 1 (01. 98), p.38-43	1-17
P, X	Bignell, G.R., et al., "Low Frequency of Somatic Mutations in the LKB1/Peutz-Jeghers Syndrome Gene in Sporadic Breast Cancer", Cancer Research, Vol. 58, No. 7 (01. 04. 98), p.1384-1386	1-17
P, X	Hemminki, A., et al., "A serine/threonine kinase gene defective in Peutz-Jeghers syndrome", Nature, Vol. 391, No. 6663 (08. 01. 98), p.184-187	6-12, 17
P, A		1-5, 13-16
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art '&' document member of the same patent family		
Date of the actual completion of the international search 9 February, 1999 (09. 02. 99)	Date of mailing of the international search report 23 February, 1999 (23. 02. 99)	
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer	
Facsimile No.	Telephone No.	